New product evaluations - a resource for medicines management

January 2017

What this is:

A list of new product evaluations that are freely available to NHS staff via the internet. The list is updated monthly, and newly published reviews are h

How to find the evaluation you want:

Look at the next tab.
Products are listed in alphabetical order, by generic drug or device name.
If a product contains two or more drugs it will be listed by brand name.
If an evaluation has been produced in the last 36 months, it will say who did it and when.
If an evaluation is currently ‘In production’ it will say who is doing it and when it is due.
Evaluations that are highlighted in red are newly-produced evaluations that have been added to the list this month.

To read the full-text evaluation:

In most cases there is a direct link to the evaluation; these are available by clicking the blue hyperlink in the ‘reviewer / publication date’ column of the

NICE: Technology appraisals are produced following a series of consultations. Information is published at specific stages of the appraisal process. If
interim documents. Please note that the publication date listed for these items is the anticipated publication date for the final appraisal.
If an evaluation has been produced in the last 36 months, it will say who did it and when.
If an evaluation is currently ‘In production’ it will say who is doing it and when it is due.
Evaluations that are highlighted in red are newly-produced evaluations that have been added to the list this month.

To read the full-text evaluation:

In most cases there is a direct link to the evaluation; these are available by clicking the blue hyperlink in the ‘reviewer / publication date’ column of the

NICE: Technology appraisals are produced following a series of consultations. Information is published at specific stages of the appraisal process. If
interim documents. Please note that the publication date listed for these items is the anticipated publication date for the final appraisal.

Who produces the evaluations?

Groups included in this list that produce evaluations are:
AWMSG – All Wales Medicines Strategy Group
LMEN - London Medicines Evaluation Network
MTRAC – Midland Therapeutic Review & Advisory Committee
NTAG –Northern Treatment Advisory Group
NICE – National Institute for Health and Care Excellence
NICE-ES – NICE Evidence Summary
NHSRIC – NIHR Horizon Scanning Research & Intelligence Centre
RDTC – Regional Drug & Therapeutics Centre
SMC – Scottish Medicines Consortium
UKMi – United Kingdom Medicines Information

Produced by North West Medicines Information Centre, The Pharmacy Practice Unit, 70 Pembroke Place,
Editor: Eimear Maguire, Telephone: 0151 794 8170; E-mail: nwmedinfo@nhs.n
nt

blished reviews are highlighted in red.

on date’ column of the table.

appraisal process. If the final appraisal is not yet available, there will be a link to available
praisal.
on date’ column of the table.

appraisal process. If the final appraisal is not yet available, there will be a link to available
praisal.

Unit, 70 Pembroke Place, Liverpool, L69 3GF.

mail: nwmedinfo@nhs.net
 Drug name Indication Reviewer / publication date

Abaloparatide Postmenopausal osteoporosis – first- and second-line NHSRIC Oct 14

Abatacept Psoriatic arthritis – second-line NHSRIC Oct 15

Abatacept Rheumatoid arthritis NICE Jan 16 (update)

Abatacept Moderate-to-severe active polyarticular juvenile idiopathic arthritis in patients aged six years and older – second-line NICE Dec 15

Abatacept Moderate-to-severe active polyarticular juvenile idiopathic arthritis in patients aged six years and older – second-line AWMSG Feb 14

Abemaciclib KRAS mutation-positive stage IV non-small cell lung cancer in patients who have progressed after platinum-based chemotherapy NHSRIC Dec 16

Abemaciclib Advanced hormone receptor-positive, HER2-negative breast cancer in postmenopausal women – first- or second-line NHSRIC Aug 16

Abiraterone Castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen NICE Jul 16

Abiraterone Hormone-naïve metastatic prostate cancer – first-line NHSRIC Oct 15

Abiraterone Asymptomatic or mildly symptomatic prostate cancer, after failure of androgen deprivation therapy, when chemotherapy is not yet clinically indicated NICE Jul 16

Abiraterone Asymptomatic or mildly symptomatic prostate cancer, after failure of androgen deprivation therapy, when chemotherapy is not yet clinically indicated SMC Oct 15

Abiraterone Asymptomatic or mildly symptomatic prostate cancer, after failure of androgen deprivation therapy, when chemotherapy is not yet clinically indicated SMC Feb 15

Abiraterone Asymptomatic or mildly symptomatic prostate cancer, after failure of androgen deprivation therapy, when chemotherapy is not yet clinically indicated AWMSG Sep 14

Abraxane (nab-paclitaxel) Non-small cell lung cancer in adults who are not candidates for potentially curative surgery and/or radiation therapy, in combination with carboplatin SMC Jun 15

Abraxane (nab-paclitaxel) Metastatic pancreatic cancer – first-line in combination with gemcitabine NICE Oct 15

Abraxane (nab-paclitaxel) Metastatic pancreatic cancer – first-line in combination with gemcitabine SMC Feb 15 (Resubmission)

Abraxane (nab-paclitaxel) Metastatic pancreatic cancer – first-line in combination with gemcitabine AWMSG Sep 14

Ace-ER (aceneuramic acid – extended release) GNE myopathy NHSRIC Mar 16

Adalimumab Moderately to severely active Crohn's disease in paediatric patients from 6 years of age AWMSG Jan 17

Adalimumab Non-infectious intermediate, posterior and panuveitis in adults SMC Nov 16

Adalimumab Moderate to severe chronic plaque psoriasis in adults who are candidates for systemic therapy SMC Jul 16

Adalimumab Uveitis in paediatric patients – second-line NHSRIC Mar 16

Adalimumab Active moderate-to-severe hidradenitis suppurativa (acne inversa) in adults – second-line NICE Jun 16

Adalimumab Active moderate-to-severe hidradenitis suppurativa (acne inversa) in adults – second-line SMC May 16
Adalimumab Active moderate-to-severe hidradenitis suppurativa (acne inversa) in adults – second-line AWMSG Sep 15

Adalimumab Psoriatic arthritis, sequential use of TNF inhibitors NTAG Sep 15 Appraisal report

Adalimumab Psoriatic arthritis, sequential use of TNF inhibitors NTAG Sep 15 Recommendation

Adalimumab Active enthesitis-related arthritis in patients aged six years and older AWMSG Jun 15

Adalimumab Active enthesitis-related arthritis in patients aged six years and older SMC May 15

Adalimumab Severe chronic plaque psoriasis in children and adolescents – second-line AWMSG Dec 15

Adalimumab Severe chronic plaque psoriasis in children and adolescents – second-line SMC Jul 15

Adalimumab Severe chronic plaque psoriasis in children and adolescents – second-line NHSRIC Dec 14

Adalimumab Ankylosing spondylitis and axial spondyloarthritis (non-radiographic) NICE Feb 16

Adalimumab Rheumatoid arthritis NICE Jan 16 (update)

Adalimumab Juvenile idiopathic arthritis, polyarticular and enthesitis-related NICE Dec 15

Adalimumab Moderate-to-severe active ulcerative colitis – second-line SMC Nov 16

Adalimumab Moderate-to-severe active ulcerative colitis – second-line NICE Feb 15

Adalimumab Moderate-to-severe active ulcerative colitis – second-line NTAG Dec 14 Appraisal report

Adalimumab Moderate-to-severe active ulcerative colitis – second-line NTAG Dec 14 Recommendation

Adapalene (Epiduo Gel) Cutaneous treatment of acne vulgaris when comedones, papules and pustules are present SMC Apr 14

Afamelanotide Generalised vitiligo – first-line in combination with narrow-band ultraviolet B light NHSRIC Jan 17

Afamelanotide Prevention of phototoxicity in adults with erythropoietic protoporphyria AWMSG due TBC (In production)

Afatinib Advanced or metastatic, squamous non-small cell lung cancer progressing on or after platinum-based chemotherapy SMC Jul 16

Afatinib Advanced or metastatic, squamous non-small cell lung cancer progressing on or after platinum-based chemotherapy NHSRIC Jan 16

Afatinib Non-small cell lung cancer SMC Mar 14

Aflibercept Visual impairment due to choroidal neovascularisation secondary to pathological myopia AWMSG due TBC (In production)

Aflibercept Visual impairment due to choroidal neovascularisation secondary to pathological myopia SMC Oct 16

Aflibercept Visual impairment due to choroidal neovascularisation secondary to pathological myopia NICE-ES Jun 16

Aflibercept Visual impairment due to choroidal neovascularisation secondary to pathological myopia NHSRIC Oct 15

In combination with FOLFIRI chemotherapy in adults with metastatic colorectal cancer that is resistant to, or has progressed after, an oxaliplatin-containing
Aflibercept AWMSG Jun 15
regimen
 In combination with FOLFIRI chemotherapy in adults with metastatic colorectal cancer that is resistant to, or has progressed after, an oxaliplatin-containing
Aflibercept NICE Mar 14
regimen
In combination with FOLFIRI chemotherapy in adults with metastatic colorectal cancer that is resistant to, or has progressed after, an oxaliplatin-containing
Aflibercept SMC Mar 14 (Resubmission)
regimen

Aflibercept Age-related macular degeneration LMEN Feb 15

Aflibercept Visual impairment due to macular oedema secondary to central retinal vein occlusion SMC Apr 14

Aflibercept Visual impairment due to macular oedema secondary to central retinal vein occlusion NICE Feb 14

Aflibercept Visual impairment due to macular oedema secondary to branch retinal vein occlusion NICE Sep 16

Aflibercept Visual impairment due to macular oedema secondary to branch retinal vein occlusion SMC Sep 15

Aflibercept Visual impairment due to macular oedema secondary to branch retinal vein occlusion NHSRIC Dec 14

Aflibercept Visual impairment due to diabetic macular oedema NICE Jul 15

Aflibercept Visual impairment due to diabetic macular oedema LMEN Apr 15

Aflibercept Visual impairment due to diabetic macular oedema SMC Nov 14

Airsonett laminar flow device Treatment of uncontrolled allergic asthma NTAG Apr 15 Appraisal report

Airsonett laminar flow device Treatment of uncontrolled allergic asthma NTAG Apr 15 Recommendation

Akynzeo (netupitant and palonosetron) Chemotherapy-induced nausea and vomiting AWMSG Jul 16

Akynzeo (netupitant and palonosetron) Chemotherapy-induced nausea and vomiting NICE-ES Mar 16

Akynzeo (netupitant and palonosetron) Chemotherapy-induced nausea and vomiting SMC Jan 16

Albiglutide Type 2 diabetes MTRAC Jul 16

Albiglutide Type 2 diabetes SMC Jan 16

Aldoxorubicin Metastatic, locally advanced or unresectable soft tissue sarcoma – second-line NHSRIC Jun 16

Alectinib Advanced ALK-positive, non-small cell lung cancer – first-line NHSRIC Aug 15

Alectinib Locally advanced or metastatic ALK-positive, non-small cell lung cancer following failure of crizotinib NHSRIC Aug 15

Alemtuzumab Multiple sclerosis, relapsing-remitting SMC Jul 14

Alemtuzumab Multiple sclerosis, relapsing-remitting NICE May 14

Alendronic acid (Binosto) Treatment of postmenopausal osteoporosis SMC Apr 16

Alfapump device Refractory ascites caused by advanced liver disease NTAG Dec 16 Appraisal report

Alfapump device Refractory ascites caused by advanced liver disease NTAG Dec 16 Recommendation
Alicaforsen Active ulcerative colitis – second-line NHSRIC Jan 16

Alirocumab Primary hypercholesterolaemia or mixed dyslipidaemia SMC Aug 16

Alirocumab Primary hypercholesterolaemia or mixed dyslipidaemia NICE Jun 16

Alirocumab Primary hypercholesterolaemia or mixed dyslipidaemia NTAG Nov 15

Alirocumab Primary hypercholesterolaemia or mixed dyslipidaemia NTAG Nov 15 Appraisal report

Alirocumab Primary hypercholesterolaemia or mixed dyslipidaemia NTAG Nov 15 Recommendation

Alisertib Relapsed or refractory peripheral T-cell lymphoma – second and subsequent line NHSRIC Mar 14

Allantoin Lesions associated with epidermolysis bullosa – first-line NHSRIC Mar 16

Alogliptin Type 2 diabetes AWMSG Oct 14

Alogliptin Type 2 diabetes SMC Oct 14 (Resubmission)

Alogliptin Type 2 diabetes MTRAC May 14

Alpha-1 antitrypsin (Respreeza) Emphysema associated with alpha-1 antitrypsin deficiency – maintenance therapy AWMSG due TBC (In production)

Alpha-1 antitrypsin (Respreeza) Emphysema associated with alpha-1 antitrypsin deficiency – maintenance therapy SMC Aug 16

Alpha-1 antitrypsin (Respreeza) Emphysema associated with alpha-1 antitrypsin deficiency – maintenance therapy NHSRIC Dec 14

Alpha-mannosidase, recombinant, human (Lamazym) Alpha mannosidosis NHSRIC May 14

Alprostadil cream Erectile dysfunction NICE-ES Dec 14

AM-111 Acute sensorineural hearing loss – first-line NHSRIC Mar 16

Anacetrapib Reduction of cardiovascular mortality and morbidity in patients at high risk of cardiovascular events – in combination with a statin NHSRIC Nov 16

Anakinra Cryopyrin-associated periodic syndromes in patients aged eight months and older with a body weight of at least 10kg SMC Dec 15

Andexanet alpha Reversal of anticoagulant effects of factor Xa inhibitors NHSRIC Apr 16

Andexanet alpha Reversal of anticoagulant effects of factor Xa inhibitors LMEN Feb 16

Anoro Ellipta (umeclidinium and vilanterol) Chronic obstructive pulmonary disease UKMi Sep 15

Anoro Ellipta (umeclidinium and vilanterol) Chronic obstructive pulmonary disease AWMSG Mar 15

Anoro Ellipta (umeclidinium and vilanterol) Chronic obstructive pulmonary disease SMC Feb 15 (Resubmission)

Anoro Ellipta (umeclidinium and vilanterol) Chronic obstructive pulmonary disease MTRAC Jan 15

Anoro Ellipta (umeclidinium and vilanterol) Chronic obstructive pulmonary disease NICE-ES Nov 14
Anti-Pseudomonas aeruginosa IgY Pseudomonal infection in cystic fibrosis NHSRIC Aug 16

Antithrombin alfa Pre-eclampsia in pre-term women NHSRIC Aug 16

Apalutamide Pre-metastatic hormone-refractory prostate cancer — add-on and substitute therapy NHSRIC Jan 17

Apixaban Treatment and prevention of venous thromboembolic events NICE Jun 15

Apixaban Treatment and prevention of venous thromboembolic events SMC Mar 15

APN311 High risk neuroblastoma in children and adolescents – first-line NHSRIC Jul 15

Apremilast Plaque psoriasis, moderate-to-severe NICE Nov 16 (Rapid review of previous guidance)

Apremilast Chronic plaque psoriasis NICE Nov 15

Apremilast Chronic plaque psoriasis SMC Jun 15

Apremilast Psoriatic arthritis NICE due Feb 17 (In production)

Apremilast Psoriatic arthritis NICE Dec 15

Apremilast Psoriatic arthritis SMC Jun 15

Aprepitant Prevention of chemotherapy-induced nausea and vomiting in patients aged between six months and 18 years AWMSG Jul 16

Aripazine Reversal of anticoagulant effect of NOACs, oral factor Xa inhibitors, fondaparinux, LMWHs and unfractionated heparins LMEN Feb 16

Aripiprazole (Abilify Maintena) Maintenance treatment of schizophrenia in adults NTAG Apr 15 Appraisal report

Aripiprazole (Abilify Maintena) Maintenance treatment of schizophrenia in adults NTAG Apr 15 Recommendation

Aripiprazole (Abilify Maintena) Maintenance treatment of schizophrenia in adults AWMSG Aug 14

Aripiprazole (Abilify Maintena) Maintenance treatment of schizophrenia in adults SMC May 14

Aripiprazole (Abilify Maintena) Maintenance treatment of schizophrenia in adults NICE-ES Mar 14

Asfotase alfa Hypophosphatasia NICE due TBC (In production - paediatric onset)

Asparaginase, erythrocyte encapsulated (GRASPA) Acute lymphoblastic leukaemia – second-line NHSRIC Feb 15

Asunaprevir, beclabuvir and daclatasvir Hepatitis C virus infection, genotype 1 – first- or second-line NHSRIC Feb 15

Ataluren CFTR class I nonsense mutation mediated cystic fibrosis NHSRIC Aug 15

Ataluren Duchenne muscular dystrophy (nonsense mutation) AWMSG Aug 16

Ataluren Duchenne muscular dystrophy (nonsense mutation) NICE Jul 16

Ataluren Duchenne muscular dystrophy (nonsense mutation) SMC Apr 16

Atezolizumab In combination with bevacizumab for advanced renal cell carcinoma – first-line NHSRIC Sep 16

Atezolizumab Locally advanced or metastatic non-small cell lung cancer – second-line NHSRIC Aug 15

Atezolizumab Urothelial bladder cancer – second and subsequent line NHSRIC Jul 15

ATIR101 Patients with haematological malignancy who are candidates for haematopoietic stem cell transplantation – adjunctive therapy NHSRIC Sep 16

Atomoxetine Attention-deficit hyperactivity disorder in children aged ≥6 years, adolescents and adults SMC Dec 15

Atomoxetine Attention-deficit hyperactivity disorder AWMSG Feb 14

Autologous haematopoietic stem cell transplantation Relapsing remitting multiple sclerosis NHSRIC Jul 16

Avacopan ANCA-associated vasculitis – first and subsequent line NHSRIC Jan 17

Avelumab Locally advanced or metastatic non-small cell lung cancer – second-line NHSRIC Dec 16

Avelumab Merkel cell carcinoma – second-line NHSRIC Mar 16

Avanafil Erectile dysfunction SMC Sep 15

Avanafil Erectile dysfunction AWMSG Jul 15

Avanafil Erectile dysfunction NICE-ES Aug 14

Avanafil Erectile dysfunction MTRAC Aug 14

Avanafil Erectile dysfunction SMC Jun 14

Avatrombopag Thrombocytopenia in chronic liver disease prior to surgery NHSRIC Oct 14

Axitinib Advanced and/or metastatic renal cell carcinoma – second-line NICE Feb 15

AXS-02 Treatment of knee pain due to osteoarthritis NHSRIC Jan 17

Azacitidine Acute myeloid leukaemia in patients aged 65 years or older with >30% marrow blasts who are not eligible for haematopoietic stem cell transplantation SMC Jul 16

Azacitidine Acute myeloid leukaemia in patients aged 65 years or older with >30% marrow blasts who are not eligible for haematopoietic stem cell transplantation NICE Jul 16

Azacitidine Acute myeloid leukaemia – first-line NHSRIC Oct 14

Azithromycin (Zedbac) Community acquired pneumonia and pelvic inflammatory disease due to susceptible organisms where initial IV treatment is required AWMSG Aug 14

Azithromycin (Zedbac) Community acquired pneumonia and pelvic inflammatory disease due to susceptible organisms where initial IV treatment is required SMC Apr 14

Azithromycin Long-term use in cystic fibrosis NICE-ES Nov 14

Azithromycin Long-term use in non-cystic fibrosis and bronchiectasis NICE-ES Nov 14

Aztreonam Suppression of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis aged six years and older – third-line SMC Jan 15 (Resubmission)
Baricitinib Moderate-to-severe rheumatoid arthritis NHSRIC Jul 15

Bavituximab Advanced non-small cell lung cancer – second-line in combination with docetaxel NHSRIC Aug 15

Bedaquiline Pulmonary multidrug resistant tuberculosis in adults AWMSG May 15

Begelomab Steroid-resistant acute graft vs. host disease NHSRIC Jul 16

Belimumab Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis NHSRIC Jan 17

SMC due May 17 (In production -

Belimumab Systemic lupus erythematosus
resubmission)

Belimumab Systemic lupus erythematosus NICE Jun 16

Benralizumab Uncontrolled asthma – second-line NHSRIC Aug 15

Betrixaban Prevention of venous thromboembolism – first-line NHSRIC Oct 14

Bevacizumab Platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer –second-line NHSRIC Dec 16

Bevacizumab Malignant pleural mesothelioma – first-line, with cisplatin and pemetrexed NHSRIC Aug 16

Bevacizumab Glioblastoma in combination with lomustine – second-line NHSRIC Oct 15

Bevacizumab EGFR-positive, advanced or metastatic non-small cell lung cancer, in combination with erlotinib – first-line SMC Sep 16

Bevacizumab EGFR-positive, advanced or metastatic non-small cell lung cancer, in combination with erlotinib – first-line NHSRIC Aug 15

Bevacizumab Wet (neovascular) age-related macular degeneration LMEN Dec 15

Bevacizumab Wet (neovascular) age-related macular degeneration NTAG Sep 14 Appraisal report update

Bevacizumab Wet (neovascular) age-related macular degeneration NTAG Sep 14 Recommendation update

Bevacizumab Macular oedema secondary to retinal vein occlusion NTAG Feb 14

Bevacizumab Recurrent or persistent stage IVB cervical cancer – in combination with chemotherapy SMC May 16

Bevacizumab Recurrent or persistent stage IVB cervical cancer – in combination with chemotherapy NHSRIC May 14

Bevacizumab Advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with paclitaxel and carboplatin – first-line SMC Nov 15 (Resubmission)

Bevacizumab Advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with paclitaxel and carboplatin – first-line SMC Jan 15 (Resubmission)

Bevacizumab Relapsed platinum-resistant ovarian cancer – second-line SMC Sep 15

Bevacizumab Relapsed platinum-resistant ovarian cancer – second-line NICE Aug 15

Bevacizumab biosimilar (BCD021) Wet age-related macular degeneration LMEN Dec 15

Bevacizumab biosimilar sustained release depot Wet age-related macular degeneration LMEN Dec 15
Bezlotoxumab Treatment and prevention of recurrence of Clostridium difficile infection NHSRIC May 16

Bimagrumab Sporadic inclusion body myositis – first-line NHSRIC Oct 15

Binimetinib Recurrent or persistent ovarian, fallopian tube or primary peritoneal cancer ─ second and subsequent line NHSRIC Jan 16

Biotin Permanent disability related to multiple sclerosis relapses – add on therapy to current immunomodulators NHSRIC Apr 15

Biotin Primary and secondary progressive multiple sclerosis ‒ first-line NHSRIC Apr 15

Birch Bark extract (Episalvan) Treatment of partial thickness wounds in adults RDTC Sept 16

Blinatumomab B-precursor acute lymphoblastic leukaemia minimal residual disease – patients in remission NHSRIC May 16

Blinatumomab Relapsed or refractory Philadelphia-positive B-precursor acute lymphoblastic leukaemia – second- or subsequent-line NHSRIC Mar 16

Blinatumomab Relapsed or refractory Philadelphia-negative B-precursor acute lymphoblastic leukaemia AWMSG Jul 16

Blinatumomab Relapsed or refractory Philadelphia-negative B-precursor acute lymphoblastic leukaemia SMC Jun 16

Blinatumomab Relapsed or refractory Philadelphia-negative B-precursor acute lymphoblastic leukaemia NHSRIC May 14

Bococizumab Primary hyperlipidaemia and mixed dyslipidaemia – adjunct to statin therapy and/or diet NHSRIC Nov 16

Mantle cell lymphoma in combination with rituximab, cyclophosphamide, doxorubicin and prednisone in patients unsuitable for haematopoietic stem cell
Bortezomib NICE Dec 15
transplantation – first-line
Mantle cell lymphoma in combination with rituximab, cyclophosphamide, doxorubicin and prednisone in patients unsuitable for haematopoietic stem cell
Bortezomib SMC Sep 15
transplantation – first-line

Bortezomib Multiple myeloma AWMSG Oct 14

Bortezomib Multiple myeloma NICE Apr 14

Bosutinib Chronic phase, accelerated phase, and blast phase Philadelphia chromosome positive chronic myelogenous leukaemia – second-line NICE Aug 16

Bosutinib Chronic phase, accelerated phase, and blast phase Philadelphia chromosome positive chronic myelogenous leukaemia – second-line SMC Feb 15 (Resubmission)

SMC due Feb 17 (In production –

Botulinum type A neurotoxin (Botox) Prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine)
resubmission)

Botulinum type A neurotoxin (Botox) Post-stroke lower limb spasticity SMC Jul 14

Botulinum type A neurotoxin (Botox) Post-stroke lower limb spasticity NHSRIC Feb 14

Botulinum toxin A (Dysport) Hyperhidrosis of the axillae NHSRIC May 16

Brentuximab vedotin Cutaneous T-cell lymphoma, CD30+ NHSRIC Jul 15

Brentuximab vedotin Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma – relapsed or refractory NICE due Feb 17 (In production)

Brentuximab vedotin Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma – relapsed or refractory AWMSG Jun 15

Brentuximab vedotin Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma – relapsed or refractory SMC Oct 14
Brimonidine Facial erythema of rosacea AWMSG Sep 15

Brimonidine Facial erythema of rosacea SMC Jan 15

Brimonidine Facial erythema of rosacea MTRAC Jul 14

Brimonidine Facial erythema of rosacea NICE-ES Jul 14

Brimonidine Facial erythema of rosacea RDTC Jun 14

Brimonidine Facial erythema of rosacea MTRAC Apr 14

Brivaracetam Partial-onset seizures, with or without secondary generalisation, in patients aged at least 16 years with epilepsy AWMSG Oct 16

Brivaracetam Partial-onset seizures, with or without secondary generalisation, in patients aged at least 16 years with epilepsy MTRAC Jul 16

Brivaracetam Partial-onset seizures, with or without secondary generalisation, in patients aged at least 16 years with epilepsy RDTC May 16

Brivaracetam Partial-onset seizures, with or without secondary generalisation, in patients aged at least 16 years with epilepsy SMC Jul 16

Brodalumab Moderate-to-severe plaque psoriasis NHSRIC May 14

Bromfenac Post-operative ocular inflammation following cataract extraction AWMSG May 14

Budesonide (Budenofalk) Autoimmune hepatitis SMC May 15

Budesonide (Budenofalk) Induction of remission in patients with mild to moderate active Crohn’s disease affecting the ileum and/or ascending colon SMC Jun 14

Budesonide (Cortiment) Induction of remission in patients with mild to moderate active ulcerative colitis SMC Oct 16

Budesonide (Cortiment) Induction of remission in patients with mild to moderate active ulcerative colitis SMC Oct 15

Budesonide (Cortiment) Induction of remission in patients with mild to moderate active ulcerative colitis UKMi Oct 15

Budesonide (Cortiment) Induction of remission in patients with mild to moderate active ulcerative colitis NICE-ES Jun 15

Buparlisib With fulvestrant for postmenopausal women with metastatic oestrogen-receptor positive, HER2 negative breast cancer – third-line NHSRIC Mar 16

Buparlisib Locally advanced or metastatic breast cancer in combination with fulvestrant NHSRIC Jul 15

Buprenorphine (Butec) Non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia SMC Jan 17

C3BS-CQR-1 (C-Cure) Heart failure secondary to ischaemic cardiomyopathy NHSRIC Mar 16

In combination with prednisone or prednisolone for treatment of hormone refractory metastatic prostate cancer previously treated with a doxetaxel-containing
Cabazitaxel SMC Dec 16 (Resubmission)
regimen
In combination with prednisone or prednisolone for treatment of hormone refractory metastatic prostate cancer previously treated with a doxetaxel-containing
Cabazitaxel SMC Jun 16
regimen
In combination with prednisone or prednisolone for treatment of hormone refractory metastatic prostate cancer previously treated with a doxetaxel-containing
Cabazitaxel NICE May 16
regimen

Cabozantinib (Cabometyx) Metastatic renal cell carcinoma – second-line SMC due May 17 (In production)
Cabozantinib (Cabometyx) Metastatic renal cell carcinoma – second-line NHSRIC Jul 15

Cabozantinib (Cometriq) Progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma SMC Mar 15

Cabozantinib (Cometriq) Progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma AWMSG Jan 15

CAM2038 Opioid dependence NHSRIC May 16

Camellia sinensis extract (green tea leaf; Catephen) External genital and perianal warts AWMSG Oct 16

Camellia sinensis extract (green tea leaf; Catephen) External genital and perianal warts SMC Apr 16

Camellia sinensis extract (green tea leaf; Catephen) External genital and perianal warts NICE-ES Dec 15

Canagliflozin Type 2 diabetes mellitus in adults – monotherapy NICE May 16

Canagliflozin Type 2 diabetes mellitus in adults – combination therapy NICE Jun 14

Canagliflozin Type 2 diabetes mellitus in adults – combination therapy SMC Jun 14

Canagliflozin Type 2 diabetes mellitus in adults – combination therapy RDTC Mar 14

Active Still's disease including Adult-Onset Still's Disease in patients who have responded inadequately to previous therapy with NSAIDs and systemic
Canakinumab SMC Nov 16
corticosteroids

Canakinumab Systemic juvenile idiopathic arthritis – second-line NICE-ES Mar 14

Cangrelor Reduction of thrombotic cardiovascular events in patients with coronary artery disease undergoing percutaneous coronary intervention NICE-ES Nov 15

Cangrelor Reduction of thrombotic cardiovascular events in patients with coronary artery disease undergoing percutaneous coronary intervention NICE Jul 15

Cangrelor Reduction of thrombotic cardiovascular events in patients with coronary artery disease undergoing percutaneous coronary intervention SMC Jun 15

Cangrelor Prevention of coronary thrombosis in patients undergoing cardiovascular surgery NICE Jul 15

Caplacizumab Thrombotic thrombocytopenic purpura NHSRIC Jul 16

Capsaicin (Qutenza) Neuropathic pain NTAG Nov 16

Capsaicin (Qutenza) Neuropathic pain NTAG Nov 16 Appraisal report

Capsaicin (Qutenza) Neuropathic pain NTAG Nov 16 Recommendation

Capsaicin (Qutenza) Peripheral neuropathic pain in adults with diabetes, either alone or in combination with other medicinal products for pain SMC Mar 16

Capsaicin (Qutenza) Peripheral neuropathic pain in adults with diabetes, either alone or in combination with other medicinal products for pain LMEN Jan 15

Capsaicin (Qutenza) Peripheral neuropathic pain in adults with diabetes, either alone or in combination with other medicinal products for pain AWMSG Dec 15

Capsaicin (Qutenza) Peripheral neuropathic pain in non-diabetic adults SMC Oct 14 (Resubmission)

Carbamazepine Aggression, agitation and behavioural disturbances in dementia NICE-ES Mar 15

 NHSRIC Jan 17
Carbavance (meropenem and vaborbactam) Treatment resistant gram-negative bacterial infections – first-line

Carfilzomib In combination with melphalan and prednisone for multiple myeloma NHSRIC Sep 16

Carfilzomib In combination with dexamethasone for relapsed multiple myeloma – second-line NHSRIC Mar 16

Carfilzomib In combination with lenalidomide and dexamethasone for adults with multiple myeloma – second plus-line SMC Jan 17 (Resubmission)

Carfilzomib In combination with lenalidomide and dexamethasone for adults with multiple myeloma – second plus-line SMC Sep 16

Cariprazine Schizophrenia in adults NHSRIC Aug 16

Cadazolid Clostridium difficile-associated diarrhoea NHSRIC May 16

Capmatinib Advanced, EGFR wild type, c-Met amplified, non-small cell lung cancer – second- or third-line NHSRIC Sep 16

Cediranib Ovarian cancer – second-line NHSRIC Mar 14

Ceftobiprole Hospital-acquired pneumonia excluding ventilator-associated pneumonia and community-acquired pneumonia SMC Jul 15

Cefuroxime (Aprokam) Antibiotic prophylaxis of postoperative endophthalmitis after cataract surgery SMC Dec 16

Cetirizine High-dose use in urticaria NICE-ES Jul 14

Ceritinib Advanced anaplastic lymphoma kinase positive non-small cell lung cancer – first-line NHSRIC Jul 16

Ceritinib ALK-positive advanced non-small cell lung cancer, previously treated with crizotinib NICE Jun 16

Ceritinib ALK-positive advanced non-small cell lung cancer, previously treated with crizotinib SMC Dec 15

Cerliponase alfa Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) NHSRIC Oct 15

Certolizumab Rheumatoid arthritis – after inadequate response to a TNF inhibitor NICE Oct 16

Certolizumab Ankylosing spondylitis and axial spondyloarthritis (non-radiographic) NICE Feb 16

Certolizumab Early rheumatoid arthritis, in combination with methotrexate NHSRIC Jul 15

Certolizumab Rheumatoid arthritis SMC May 16

Certolizumab Rheumatoid arthritis NICE Jan 16 (update)

Certolizumab Adults with severe active axial spondyloarthritis SMC May 14

Certolizumab Psoriatic arthritis, sequential use of TNF inhibitors NTAG Sep 15 Appraisal report

Certolizumab Psoriatic arthritis, sequential use of TNF inhibitors NTAG Sep 15 Recommendation

Certolizumab Active psoriatic arthritis – second-line NICE due Feb 17 (In production)

Certolizumab Active psoriatic arthritis – second-line NTAG Sep 15 Appraisal report

Certolizumab Active psoriatic arthritis – second-line NTAG Sep 15 Recommendation

Certolizumab Active psoriatic arthritis – second-line AWMSG Oct 14

Certolizumab Active psoriatic arthritis – second-line SMC Jul 14

Certolizumab Active psoriatic arthritis – second-line NICE-ES Jun 14

Cetuximab Head and neck cancer (squamous cell carcinoma) NICE due Mar 17 (In production – rapid review)

Cetuximab Metastatic colorectal cancer, RAS wild-type patients AWMSG Jan 16

Cetuximab Metastatic colorectal cancer, RAS wild-type patients SMC Jan 15

Cholecalciferol (InVita D3) Prevention and treatment of vitamin D deficiency SMC Dec 14

Cholic acid (Orphacol) Inborn errors of primary bile acid synthesis – first-line NHSRIC Mar 14

Ciclosporin Severe keratitis in adults with dry eye disease – second-line NICE Dec 15

Ciclosporin Severe keratitis in adults with dry eye disease – second-line SMC Oct 15

Ciclosporin Reperfusion injury prevention prior to percutaneous coronary intervention for ST-segment elevation acute myocardial infarction NHSRIC May 14

Ciraparantag Haemorrhage in patients receiving new oral anticoagulants NHSRIC Sep 16

Clostridium botulinum type A (Xeomin) Sialorrhoea associated with adult Parkinson’s disease and paediatric cerebral palsy NHSRIC Apr 15

Cobicistat HIV-1 infection SMC May 14

Cobimetinib BRAF V600-positive, unresectable, locally advanced or metastatic melanoma with vemurafenib NICE Oct 16

Cobimetinib BRAF V600-positive, unresectable, locally advanced or metastatic melanoma with vemurafenib SMC Sep 16

Cobimetinib BRAF V600-positive, unresectable, locally advanced or metastatic melanoma with vemurafenib NHSRIC Aug 14

Co-careldopa (Duodopa) Advanced levodopa-responsive Parkinson’s disease – second-line SMC Jun 16 (resubmission)

Co-careldopa (Duodopa) Advanced levodopa-responsive Parkinson’s disease – second-line SMC Dec 15

Co-enzyme Q10 Mitochrondial disorders NICE due Mar 17 (In production)

Colestilan Hyperphosphataemia in adults with chronic kidney disease on dialysis SMC Feb 15

Colestilan Hyperphosphataemia in adults with chronic kidney disease on dialysis AWMSG Oct 14

Colestilan Hyperphosphataemia in adults with chronic kidney disease on dialysis SMC Aug 14 (resubmission)

Collagenase clostridium histolyticum Dupuytren’s contracture NICE due TBC (In production)

Collagenase clostridium histolyticum Peyronie’s disease – first-line LMEN Aug 15

Collagenase clostridium histolyticum Peyronie’s disease – first-line SMC May 15

Collagenase clostridium histolyticum Peyronie’s disease – first-line NHSRIC Dec 14

Conbercept Wet age-related macular oedema LMEN Dec 15

Cositecan Advanced mucinous epithelial ovarian cancer – second-line NHSRIC Aug 14

CPX-351 (VYXEOS) Elderly patients with newly diagnosed acute myeloid leukaemia – first-line NHSRIC Mar 16

Crisaborole Adults, adolescents and children with atopic dermatitis NHSRIC Apr 16

Crizotinib Advanced ROS1-positive non-small cell lung cancer – first-line NHSRIC Jun 16

Crizotinib Advanced non-small cell lung cancer, ALK-positive, previously treated NICE Dec 16 (Rapid review)

Crizotinib Non-small cell lung cancer, ALK-positive, locally advanced or metastatic – first-line NICE Sep 16

Crizotinib Non-small cell lung cancer, ALK-positive, locally advanced or metastatic – first-line SMC Jul 16

Crizotinib Non-small cell lung cancer, ALK-positive, locally advanced or metastatic – first-line NHSRIC Feb 15

Cryopreserved human placental tissue Wound repair NHSRIC Sep 16

CTL019 Relapsed or refractory B-cell acute lymphoblastic leukaemia NHSRIC Nov 16

Custirsen Advanced, unresectable non-small cell lung cancer – second-line, in combination with docetaxel NHSRIC Aug 16

Custirsen Locally advanced or metastatic hormone-relapsed prostate cancer – first and second-line NHSRIC Feb 14

Cx601 (Alofisel) Complex perianal fistula in adults with luminal Crohn’s disease – second-line NHSRIC Apr 15

Cytovir CMV Cytomegalovirus infection in patients undergoing allogeneic haematopoietic stem cell transplantation NHSRIC Jan 16

Dabigatran Treatment of acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE) and prevention of recurrent DVT and PE NICE Dec 14

Dabigatran Treatment of acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE) and prevention of recurrent DVT and PE SMC Oct 14

Dabrafenib BRAF V600-positive melanoma – adjuvant therapy after surgical resection in combination with trametinib NHSRIC Sep 16

Dabrafenib Advanced BRAF V600E-positive non-small cell lung cancer – all lines of therapy in combination with trametinib NHSRIC Apr 16

Dabrafenib Advanced BRAF V600E-positive non-small cell lung cancer – second-line in combination with trametinib NHSRIC Aug 15

Dabrafenib Unresectable or metastatic melanoma with a BRAF V600 mutation in adults – in combination with trametinib SMC Sep 16

Dabrafenib Unresectable or metastatic melanoma with a BRAF V600 mutation in adults – in combination with trametinib NICE Jun 16

Dabrafenib Unresectable or metastatic melanoma with a BRAF V600 mutation in adults – monotherapy SMC Mar 15

Dabrafenib Unresectable or metastatic melanoma with a BRAF V600 mutation in adults – monotherapy NICE Oct 14
Daclatasvir Chronic hepatitis C virus infection in adults NICE Nov 15

Daclatasvir Chronic hepatitis C virus infection in adults AWMSG May 15

Daclatasvir Chronic hepatitis C virus infection in adults SMC Nov 14

Daclizumab Multiple sclerosis (relapsing-remitting) SMC due Apr 17 (In production)

Daclizumab Multiple sclerosis (relapsing-remitting) NICE due Jan 17 (In production-overdue)

Daclizumab Relapsing forms of multiple sclerosis – first- or second-line NHSRIC Aug 14

Daclatasvir and sofosbuvir Chronic hepatitis C infection with and without ribavirin NHSRIC Mar 14

Dacomitinib Locally advanced or metastatic EGFR positive non-small cell lung cancer – first-line NHSRIC Oct 15

Dalbavancin Acute bacterial skin and skin structure infections in adults SMC Jan 17

Danazol (ultra-low-dose) Diabetic macular oedema NHSRIC Mar 16

Dapagliflozin Type 2 diabetes mellitus – as part of triple therapy regimens NICE Nov 16

Dapagliflozin Type 2 diabetes mellitus – monotherapy NICE May 16

Dapagliflozin Type 2 diabetes mellitus – combination therapy SMC Jul 14 (Resubmission)

Dapoxetine Premature ejaculation SMC Jul 14

Dapoxetine Premature ejaculation NTAG Jun 14 Appraisal report

Dapoxetine Premature ejaculation NTAG Jun 14 Recommendation

Dapoxetine Premature ejaculation NICE-ES May 14

Daptomycin Treatment of paediatric patients (1 to 17 years) with complicated skin and soft-tissue infections SMC Mar 16

Daratumumab Relapsed or refractory multiple myeloma – second-line in combination with bortezomib and dexamethasone SMC due Jan 17 (In production-overdue)

Daratumumab Relapsed or refractory multiple myeloma – second-line in combination with bortezomib and dexamethasone NHSRIC Jan 16

Daratumumab Relapsed or refractory multiple myeloma – monotherapy SMC Jan 17

Daratumumab Relapsed or refractory multiple myeloma – monotherapy NHSRIC Aug 15

Daratumumab Relapsed or refractory multiple myeloma, with lenalidomide and dexamethasone NHSRIC Aug 15

Darbepoetin Cancer treatment-induced anaemia NICE Nov 14

Darunavir HIV-1 infection in patients aged 12 to 17 years and weighing at least 40kg AWMSG May 14

Darunavir HIV-1 infection in patients aged 12 to 17 years and weighing at least 40kg SMC Mar 14
Darunavir HIV-1 infection in antiretroviral-experienced children aged at least 3 years and weighing at least 15kg, with low-dose ritonavir and other antiretrovirals AWMSG Jul 15

Darunavir HIV-1 infection in antiretroviral-experienced children aged at least 3 years and weighing at least 15kg, with low-dose ritonavir and other antiretrovirals SMC Jul 15

Dasabuvir Chronic hepatitis C in adults, in combination with Viekirax (ombitasvir, paritaprevir and ritonavir), with or without ribavirin SMC Jun 15

Dasatinib Adults with chronic- or accelerated-phase chronic myeloid leukaemia with resistance or intolerance to imatinib NICE Dec 16

Dasatinib Adults with chronic-, accelerated- or blast-phase chronic myeloid leukaemiawith resistance or intolerance to prior therapy including imatinib SMC Sep 16

Dasatinib Adults with untreated Philadelphia chromosome positive chronic myeloid leukaemia in the chronic phase NICE Dec 16

Dasatinib Adults with untreated Philadelphia chromosome positive chronic myeloid leukaemia in the chronic phase SMC Sep 16

Decitabine Acute myeloid leukaemia – first-line NHSRIC Jul 16

Deferasirox Chronic iron overload in patients with myelodysplastic syndrome with International Prognostic Scoring System score of low or intermediate -1 risk SMC Jan 17 (Resubmission)

Defibrotide Hepatic veno-occlusive disease in patients undergoing haematopoietic stem-cell transplantation AWMSG May 15

Defibrotide Hepatic veno-occlusive disease in patients undergoing haematopoietic stem-cell transplantation SMC Jun 14

Degarelix Advanced hormone-dependent prostate cancer NICE Aug 16

Delta-9-tetrahydrocannabinol/cannabidiol (Sativex) Symptom improvement in adults with moderate-to-severe spasticity due to multiple sclerosis – second-line AWMSG Aug 14

Denosumab (Prolia) Osteoporosis in men at increased risk of fractures SMC Nov 14

Denosumab (Prolia) Glucocorticoid-induced osteoporosis NHSRIC Mar 14

Denosumab (Xgeva) Hypercalcaemia of malignancy – second-line NHSRIC Sep 16

Denosumab (Xgeva) Giant cell tumour of bone in adults and skeletally-mature adolescents AWMSG Dec 15

Depatuxizumab mafodotin Recurrent EGFR-amplified glioblastoma multiforme NHSRIC Sep 16

Dequalinium chloride Bacterial vaginosis AWMSG Nov 16

Dequalinium chloride Bacterial vaginosis SMC Nov 16

In combination with other antiretrovirals for treatment of adults and adolescents (aged 12 years and older with body weight ≥35 kg) with human
Descovy (emtricitabine/tenofovir alafenamide) AWMSG Oct 16
immunodeficiency virus type 1
In combination with other antiretrovirals for treatment of adults and adolescents (aged 12 years and older with body weight ≥35 kg) with human
Descovy (emtricitabine/tenofovir alafenamide) SMC Aug 16
immunodeficiency virus type 1

Desmopressin lyophilisate (Noqdirna) Nocturia in adults SMC due Feb 17 (In production)

Desmopressin lyophilisate (Noqdirna) Nocturia in adults NHSRIC Jul 16

Dexamethasone intratympanic injection (OTO-104) Meniere's disease NHSRIC Nov 16

Dexamethasone intracanalicular insert (Dextenza) Pain and inflammation following cataract surgery NHSRIC Nov 16
Dexamethasone intravitreal implant (Ozurdex) Diabetic macular oedema NICE Jul 15

Dexamethasone intravitreal implant (Ozurdex) Diabetic macular oedema SMC May 15

Dexamethasone intravitreal implant (Ozurdex) Diabetic macular oedema LMEN Sep 14

Dexamethasone intravitreal implant (Ozurdex) Diabetic macular oedema NTAG Feb 14

Diamorphine hydrochloride (Ayendi) Treatment of severe nociceptive pain in children and adolescents 2 to15 years of age in a hospital setting SMC Aug 16

Diazoxide choline controlled-release Prader-Willi syndrome – first-line NHSRIC Sep 16

Diclectin (doxylamine succinate/pyridoxine hydrochloride) Nausea and vomiting in pregnancy NHSRIC Mar 16

Dimethyl fumarate (Tecfidera) Relapsing-remitting multiple sclerosis NICE Aug 14

Dimethyl fumarate (Tecfidera) Relapsing-remitting multiple sclerosis SMC Apr 14

Dimethyl sulfoxide 50% Interstitial cystitis NICE-ES Feb 14

Dinutuximab High risk neuroblastoma – maintenance therapy SMC due TBC (In production)

Dinutuximab High risk neuroblastoma – maintenance therapy NHSRIC May 14

DMI-9523 (Ampion) Moderate to severe osteoarthritis of the knee NHSRIC Mar 16

Docetaxel Hormone-sensitive metastatic prostate cancer NICE-ES Jan 16

Dolutegravir HIV infection AWMSG Sep 14

Dolutegravir HIV infection SMC May 14

Donepezil Alzheimer's disease NICE May 16

Doxorubicin, pegylated liposomal Ovarian cancer – advanced, recurrent NICE Apr 16

Doxorubicin-eluting beads Hepatocellular carcinoma NHSRIC Jan 16

Drisapersen Duchenne’s muscular dystrophy – first-line NICE due TBC (In production)

Duaklir Genuair (aclidinium and formoterol) Chronic obstructive pulmonary disease NICE-ES Apr 15

Duaklir Genuair (aclidinium and formoterol) Chronic obstructive pulmonary disease SMC Apr 15

Duaklir Genuair (aclidinium and formoterol) Chronic obstructive pulmonary disease RDTC Mar 15

Duaklir Genuair (aclidinium and formoterol) Chronic obstructive pulmonary disease MTRAC Jan 15

Duavive (conjugated oestrogens and bazedoxifene) Treatment of oestrogen deficiency symptoms in postmenopausal women SMC Jan 17

Duavive (conjugated oestrogens and bazedoxifene) Treatment of oestrogen deficiency symptoms in postmenopausal women NICE-ES Dec 16
Dulaglutide Type 2 diabetes MTRAC Jul 16

Dulaglutide Type 2 diabetes AWMSG Jun 16

Dulaglutide Type 2 diabetes SMC Jan 16

Dulaglutide Type 2 diabetes NICE-ES Jun 15

DuoResp Spiromax (budesonide and formoterol fumarate) Chronic obstructive pulmonary disease MTRAC Jan 15

Dupilumab Bilateral nasal polyposis and chronic sinusitis – second-line NHSRIC Jan 17

Dupilumab Moderate-to-severe atopic dermatitis – second-line NHSRIC Jul 16

Durvalumab Locally advanced, unresectable non-small cell lung cancer – sequential therapy following platinum-based chemoradiation NHSRIC Jan 17

Durvalumab EGFR and ALK wild-type, advanced or metastatic non-small cell lung cancer – first-line in combination with tremelimumab NHSRIC Dec 16

Durvalumab Recurrent or metastatic squamous cell carcinoma of the head and neck – second-line in combination with tremelimumab NHSRIC Dec 16

Durvalumab Locally advanced or metastatic urothelial bladder cancer – second-line NHSRIC Nov 16

Durvalumab Recurrent or metastatic PD-L1 negative or positive squamous cell carcinoma of the head and neck – second-line NHSRIC Sep 16

Duvelisib Relapsed follicular lymphoma – second- and subsequent-line NHSRIC May 16

Duvelisib Relapsed chronic lymphocytic leukaemia – second- and subsequent-line NHSRIC May 16

Dymista (azelastine and fluticasone) Allergic rhinitis SMC Oct 14 (Resubmission)

Eculizumab Relapsing neuromyelitis optica spectrum disorders NHSRIC Sep 16

Eculizumab Prevention of delayed graft function after kidney transplantation in adults at increased risk – first-line NHSRIC Sep 16

Eculizumab Refractory myasthenia gravis NHSRIC Apr 16

Eculizumab C3 glomerulopathy in the native kidney NICE-ES Dec 15

Eculizumab Prevention of recurrence of C3 glomerulopathy post-transplant NICE-ES Jun 15

Eculizumab Atypical haemolytic uraemic syndrome SMC Feb 16

Eculizumab Atypical haemolytic uraemic syndrome AWMSG Aug 15

Eculizumab Atypical haemolytic uraemic syndrome NICE Jan 15

Eculizumab Paroxysmal nocturnal haemoglobinuria SMC Apr 16

Edoxaban Treatment and prevention of venous thromboembolism in adults SMC Nov 15

Edoxaban Treatment and prevention of venous thromboembolism in adults NICE Aug 15

Edoxaban Prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation and other risk factors MTRAC due TBC (In production)

Edoxaban Prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation and other risk factors SMC Nov 15

Edoxaban Prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation and other risk factors NICE Sep 15

Edoxaban Prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation and other risk factors RDTC Jun 15

Efavirenz HIV-1 infection children aged three months to three years and weighing at least 3.5kg AWMSG Jan 16

Efavirenz HIV-1 infection children aged three months to three years and weighing at least 3.5kg SMC Dec 15

Eleclazine Hypertrophic cardiomyopathy NHSRIC Aug 16

Eliglustat Gaucher disease (type 1) NICE due TBC (In production)

Elosulfase alfa Mucopolysaccaridosis, type IV (Morquio A Syndrome, MPS IVA) NICE Dec 15

Elosulfase alfa Mucopolysaccaridosis, type IV (Morquio A Syndrome, MPS IVA) SMC Sep 15

Elotuzumab Multiple myeloma in combination with lenalidomide and dexamethasone in adults who have received at least one prior therapy SMC Aug 16

Elotuzumab Multiple myeloma in combination with lenalidomide and dexamethasone – first-line NHSRIC Jul 15

Eltrombopag Severe aplastic anaemia – second-line SMC Jun 16

Eltrombopag Severe aplastic anaemia – second-line NHSRIC Oct 14

Eltrombopag Thrombocytopenia in adults with chronic hepatitis C infection AWMSG Jul 14

Eltrombopag Chronic immune thrombocytopenic purpura in children from the age of 1 year to <18 years SMC Jan 17

Eltrombopag Chronic immune thrombocytopenic purpura in children from the age of 1 year to <18 years AWMSG Oct 16

Eltrombopag Chronic immune thrombocytopenic purpura in children from the age of 1 year to <18 years NHSRIC Aug 14

Eluxadoline Irritable bowel syndrome (diarrhoea-predominant) – first-line MTRAC due TBC (In production)

Eluxadoline Irritable bowel syndrome (diarrhoea-predominant) – first-line NTAG Sep 16 Appraisal report

Eluxadoline Irritable bowel syndrome (diarrhoea-predominant) – first-line NTAG Sep 16 Recommendation

Eluxadoline Irritable bowel syndrome (diarrhoea-predominant) – first-line NHSRIC Oct 14

Empagliflozin Preventing cardiovascular death in patients with type 2 diabetes mellitus and high cardiovascular risk NHSRIC Jun 16

Empagliflozin Type 1 diabetes – adjunctive therapy NHSRIC Jun 16

Empagliflozin Type 2 diabetes – monotherapy NICE May 16

Empagliflozin Type 2 diabetes – combination therapy AWMSG Jan 16

Empagliflozin Type 2 diabetes – combination therapy NICE Mar 15

Empagliflozin Type 2 diabetes – combination therapy SMC Oct 14

Encorafenib BRAF V600 mutation-positive melanoma with binimetinib – first- and second-line NHSRIC Oct 14

Enstilar (calcipotriol/betamethasone) Psoriasis vulgaris in adults SMC Sep 16

Entecavir Chronic hepatitis B virus infection in nucleoside-naive patients aged two to 18 years AWMSG May 15

Entecavir Chronic hepatitis B virus infection in nucleoside-naive patients aged two to 18 years SMC May 15

Enzalutamide Metastatic castration-resistant prostate cancer after failure of androgen deprivation therapy when chemotherapy is not yet clinically indicated SMC Mar 16

Enzalutamide Metastatic castration-resistant prostate cancer after failure of androgen deprivation therapy when chemotherapy is not yet clinically indicated NICE Jan 16

Enzalutamide Metastatic castration-resistant prostate cancer after failure of androgen deprivation therapy when chemotherapy is not yet clinically indicated AWMSG Sep 15

Enzalutamide Metastatic castration-resistant prostate cancer after failure of androgen deprivation therapy when chemotherapy is not yet clinically indicated SMC Aug 15

Enzalutamide Metastatic castration‑resistant prostate cancer, after docetaxel therapy NICE Jun 14

Epclusa (sofosbuvir and velpatasvir) Chronic hepatitis C NICE Jan 17

Epclusa (sofosbuvir and velpatasvir) Chronic hepatitis C AWMSG Nov 16

Epclusa (sofosbuvir and velpatasvir) Chronic hepatitis C SMC Nov 16

Epoetin Cancer-treatment induced anaemia NICE Nov 14

Epoetin alfa (Eprex) Anaemia in adults with low or intermediate-1 risk myelodysplastic syndromes NHSRIC Jun 16

Epratuzumab Systemic lupus erythematosus NHSRIC Feb 15

Eprodisate disodium AA amyloidosis NHSRIC Oct 15

Erenumab Prophylaxis of migraine NHSRIC Aug 16

Eribulin AWMSG May 16

Locally advanced or metastatic breast cancer – second-line

Eribulin SMC Mar 16 (Resubmission)

Locally advanced or metastatic breast cancer – second-line

Eribulin SMC Aug 15

Locally advanced or metastatic breast cancer – second-line

Erlotinib Non-small-cell lung cancer that has progressed following prior chemotherapy NICE Dec 15

Ertugliflozin Type 2 diabetes mellitus NHSRIC Nov 16

Etanercept Ankylosing spondylitis and axial spondyloarthritis (non-radiographic) NICE Feb 16

Etanercept Psoriatic arthritis, sequential use of TNF inhibitors NTAG Sep 15 Appraisal report
Etanercept Psoriatic arthritis, sequential use of TNF inhibitors NTAG Sep 15 Recommendation

Etanercept Juvenile idiopathic arthritis, polyarticular, psoriatic and enthesitis-related NICE Dec 15

Etanercept Rheumatoid arthritis NICE Jan 16 (Update)

Etanercept biosimilar (Benepali) All etanercept licensed indications NTAG Apr 16 Appraisal report

Etanercept biosimilar (Benepali) All etanercept licensed indications NTAG Apr 16 Recommendation

Etanercept biosimilar (Benepali) All etanercept licensed indications LMEN Feb 16

Etanercept biosimilar (Benepali) All etanercept licensed indications UKMi Jan 16

Eteplirsen Duchenne muscular dystrophy in patients amenable to exon 51 skipping NHSRIC Mar 16

Etirinotecan pegol Metastatic breast cancer - second or subsequent line NHSRIC Mar 14

e-Voke inhaler Smoking cessation – first-line NTAG Apr 16 Appraisal report

e-Voke inhaler Smoking cessation – first-line NTAG Apr 16 Recommendation

e-Voke inhaler Smoking cessation – first-line NHSRIC Apr 16

Unresectable or metastatic, well-differentiated (Grade 1 or Grade 2), non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with
Everolimus SMC due Feb 17 (In production)
progressive disease

Everolimus Diffuse large B-cell lymphoma – maintenance therapy NHSRIC Apr 16

Hormone receptor-positive, HER2-negative advanced breast cancer in postmenopausal women without symptomatic visceral disease after recurrence or
Everolimus NICE due Feb 17 (In production-rapid review)
progression following a non-steroidal aromatase inhibitor – in combination with exemestane
Hormone receptor-positive, HER2-negative advanced breast cancer in postmenopausal women without symptomatic visceral disease after recurrence or
Everolimus SMC Apr 16 (Resubmission)
progression following a non-steroidal aromatase inhibitor – in combination with exemestane

Everolimus Advanced breast cancer after endocrine therapy – in combination with exemestane NICE Dec 16 (Rapid review)

Everolimus Advanced breast cancer after endocrine therapy – in combination with exemestane SMC Oct 15 (Resubmission)

Everolimus Advanced renal cell carcinoma that has progressed on or after treatment with VEGF-targeted therapy NICE due Mar 17 (In production-rapid review)

Everolimus Advanced renal cell carcinoma that has progressed on or after treatment with VEGF-targeted therapy SMC Nov 14 (Resubmission)

Everolimus Prevention of organ rejection in allogeneic liver transplantation NICE Jul 15

Eviplera (emtricitabine, rilpivirine and tenofovir) HIV-1 infection in adults AWMSG Jul 14

Eviplera (emtricitabine, rilpivirine and tenofovir) HIV-1 infection in adults SMC Apr 14

Evofosfamide Locally advanced, unresectable or metastatic pancreatic cancer – first-line in combination with gemcitabine NHSRIC Apr 15

Evofosfamide Locally advanced or metastatic, unresectable soft tissue sarcoma – first-line, in combination with doxorubicin NHSRIC Dec 14

Evolocumab Cardiovascular event prevention – add on therapy NHSRIC Nov 16

 SMC due Feb 17 (In production –
Evolocumab Primary hypercholesterolaemia and mixed dyslipidaemia
resubmission)

Evolocumab Primary hypercholesterolaemia and mixed dyslipidaemia AWMSG Jul 16

Evolocumab Primary hypercholesterolaemia and mixed dyslipidaemia SMC Jun 16

Evolocumab Primary hypercholesterolaemia and mixed dyslipidaemia NICE Jun 16

Evolocumab Primary hypercholesterolaemia and mixed dyslipidaemia NTAG Nov 15 Appraisal report

Evolocumab Primary hypercholesterolaemia and mixed dyslipidaemia NTAG Nov 15 Recommendation

Evotaz (atazanavir and cobicistat) HIV-1 infection in adults AWMSG Jan 16

Evotaz (atazanavir and cobicistat) HIV-1 infection in adults SMC Nov 15

Exenatide (Bydureon) Type 2 diabetes MTRAC Jul 16

Exenatide (Byetta) Type 2 diabetes MTRAC Jul 16

Ex vivo lentiviral gene therapy Severe combined immunodeficiency caused by adenosine deaminase deficiency NHSRIC Sep 16

Ezetimibe Hypercholesterolaemia NICE Feb 16

Fampridine Improvement of walking in adults with multiple sclerosis with walking disability SMC Nov 16

Fampridine Improvement of walking in adults with multiple sclerosis with walking disability AWMSG Sep 14

Febuxostat Hyperuricaemia in adults undergoing chemotherapy for haematologic malignancies at intermediate to high risk of tumor lysis syndrome SMC Jun 16

Fenfluramine Dravet syndrome – first-line NHSRIC Jan 16

Fentanyl (IONSYS) Management of acute moderate to severe post-operative pain in adults SMC Dec 16

Fentanyl (IONSYS) Management of acute moderate to severe post-operative pain in adults NICE-ES Jun 16

Ferric maltol (Feraccru) Iron deficiency anaemia in adults with inflammatory bowel disease AWMSG due TBC (In production)

Ferric maltol (Feraccru) Iron deficiency anaemia in adults with inflammatory bowel disease SMC Dec 16

Ferric maltol (Feraccru) Iron deficiency anaemia in adults with inflammatory bowel disease NTAG Sep 16 Appraisal report

Ferric maltol (Feraccru) Iron deficiency anaemia in adults with inflammatory bowel disease NTAG Sep 16 Recommendation

Ferric maltol (Feraccru) Iron deficiency anaemia in adults with inflammatory bowel disease LMEN Jun 16

Fingolimod Highly active relapsing remitting multiple sclerosis in adults – use as a single disease modifying therapy AWMSG Jan 17

Fingolimod Chronic inflammatory demyelinating polyneuropathy – second-line NHSRIC Aug 14

Rapidly evolving severe relapsing–remitting multiple sclerosis and patients with high disease activity despite treatment with at least one disease modifying
Fingolimod SMC Apr 15
therapy
 Rapidly evolving severe relapsing–remitting multiple sclerosis and patients with high disease activity despite treatment with at least one disease modifying
Fingolimod SMC Oct 14
therapy

Flunarizine Migraine prevention – second-line NICE-ES Sep 14

Fluocinolone acetonide (Medidur) Non-infectious posterior uveitis – second-line NHSRIC Jun 16

Fluocinolone intravitreal implant Diabetic macular oedema SMC Feb 14 (Resubmission)

Fluoxetine Hypersexuality NICE-ES Jul 15

Flutiform (fluticasone propionate and formoterol) Asthma MTRAC Nov 15

Follicle stimulating hormone biosimilar (Bemfola) Fertility disorders SMC Feb 15

Follicle stimulating hormone biosimilar (Bemfola) Fertility disorders AWMSG Jan 15

Fortacin (lidocaine and prilocaine spray) Premature ejaculation RDTC Oct 15 (Update)

Treatment of infections in adults and children including neonates: acute osteomyelitis; complicated urinary tract infections; nosocomial lower respiratory tract
Fosfomycin AWMSG Nov 15
infections; bacterial meningitis; bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above

Treatment of infections in adults and children including neonates: acute osteomyelitis; complicated urinary tract infections; nosocomial lower respiratory tract
Fosfomycin SMC Mar 15
infections; bacterial meningitis; bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above

Acute lower uncomplicated urinary tract infections, caused by pathogens sensitive to fosfomycin in adult and adolescent females; prophylaxis in diagnostic and
Fosfomycin trometamol (Monuril) SMC Sep 16
surgical transurethral procedures

Fostair (beclometasone and formoterol) Asthma MTRAC Nov 15

Fostair (beclometasone and formoterol) Asthma NICE-ES Jan 15 (NEXThaler)

Fostair (beclometasone and formoterol) Chronic obstructive pulmonary disease AWMSG Jun 15

Fostair (beclometasone and formoterol) Chronic obstructive pulmonary disease MTRAC Jan 15

Fostair (beclometasone and formoterol) Chronic obstructive pulmonary disease NICE-ES Sep 14

Fostair (beclometasone and formoterol) Chronic obstructive pulmonary disease SMC Jul 14

Fostamatinib Chronic immune thrombocytopenic purpura NHSRIC May 16

FreeStyle Libre Flash Glucose Monitoring System Flash blood glucose monitoring NTAG Sep 16 Appraisal report

FreeStyle Libre Flash Glucose Monitoring System Flash blood glucose monitoring NTAG Sep 16 Recommendation

Fulvestrant Hormone-receptor positive breast cancer, advanced or metastatic – first-line NHSRIC Oct 15

Fulvestrant Hormone-receptor positive breast cancer, advanced or metastatic – relapsed or progressive disease SMC Feb 16

Furosemide sc2Wear micro-pump patch Oedema in heart failure NHSRIC Apr 16

Gabapentin (topical) Neuropathic pain RDTC Nov 15

Galantamine Alzheimer’s disease NICE May 16

Gefitinib Locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR SMC Dec 15 (Resubmission)

Gefitinib Non-small cell lung cancer that has progressed following prior chemotherapy NICE Dec 15

Gemcitabine Ovarian cancer – advanced, recurrent NICE Apr 16

Gemtuzumab ozogamicin Acute myeloid leukaemia, with conventional chemotherapy – first-line NHSRIC Aug 15

Genvoya (elvitegravir, cobicistat, emtricitabine and

HIV-1 infection in adults and adolescents aged over 12 years and weighing at least 35kg AWMSG Jul 16
tenofovir alafenamide fumarate)
Genvoya (elvitegravir, cobicistat, emtricitabine and
HIV-1 infection in adults and adolescents aged over 12 years and weighing at least 35kg SMC May 16
tenofovir alafenamide fumarate)

Glatiramer acetate Relapsing forms of multiple sclerosis SMC Dec 15

Glecaprevir and pibrentasvir Chronic hepatitis C infection, genotypes 1, 2, 3, 4, 5 and 6 NHSRIC May 16

Glycerol phenylbutyrate Urea cycle disorders (hyperammonaemia) NHSRIC Aug 15

Glycopyrronium Treatment of hypersalivation in children and young people aged 3 years and older with chronic neurological disorders NICE-ES due Feb 17 (In production)

Glyxambi (empaglifozin and linagliptin) Type 2 diabetes mellitus in adults SMC due May 17 (In production)

In combination with methotrexate for treatment of polyarticular juvenile idiopathic arthritis in children with a body weight of at least 40 kg, who have responded
Golimumab SMC Oct 16
inadequately to previous therapy with methotrexate.

Golimumab Moderate-to-severe active ulcerative colitis in adults – second-line NICE Feb 15

Golimumab Moderate-to-severe active ulcerative colitis in adults – second-line NTAG Dec 14 Appraisal report

Golimumab Moderate-to-severe active ulcerative colitis in adults – second-line NTAG Dec 14 Recommendation

Golimumab Moderate-to-severe active ulcerative colitis in adults – second-line SMC Oct 14

Golimumab Moderate-to-severe active ulcerative colitis in adults – second-line LMEN Mar 14

Golimumab Axial spondyloarthritis (non-radiographic) AWMSG Oct 16

Golimumab Axial spondyloarthritis (non-radiographic) SMC Feb 16

Golimumab Ankylosing spondylitis and axial spondyloarthritis (non-radiographic) NICE Feb 16

Golimumab Psoriatic arthritis, sequential use of TNF inhibitors NTAG Sep 15 Appraisal report

Golimumab Psoriatic arthritis, sequential use of TNF inhibitors NTAG Sep 15 Recommendation

Golimumab Rheumatoid arthritis NICE Jan 16 (Update)

GS-6615 Long QT-3 syndrome NHSRIC Jul 15

GSK2696273 Severe combined immunodeficiency due to adenosine deaminase deficiency NHSRIC Aug 15
Guanfacine Attention deficit hyperactivity disorder in children and adolescents aged six to 17 years – second-line LMEN Jul 16

Guanfacine Attention deficit hyperactivity disorder in children and adolescents aged six to 17 years – second-line AWMSG Jun 16

Guanfacine Attention deficit hyperactivity disorder in children and adolescents aged six to 17 years – second-line NICE-ES Mar 16

Guanfacine Attention deficit hyperactivity disorder in children and adolescents aged six to 17 years – second-line RDTC Feb 16

Guanfacine Attention deficit hyperactivity disorder in children and adolescents aged six to 17 years – second-line SMC Feb 16

Guselkumab Moderate-to-severe psoriasis NHSRIC Jan 16

Harvoni (ledipasvir and sofosbuvir) Chronic hepatitis C in adults – genotype 3 SMC Sep 15

Harvoni (ledipasvir and sofosbuvir) Chronic hepatitis C in adults NICE Nov 15

Harvoni (ledipasvir and sofosbuvir) Chronic hepatitis C in adults AWMSG Aug 15

Harvoni (ledipasvir and sofosbuvir) Chronic hepatitis C in adults SMC Mar 15

Heartcel Heart failure in patients at risk of incomplete revascularisation following coronary artery bypass graft NHSRIC Apr 16

Hexyl aminolevulinate Cervical high-grade squamous intraepithelial lesions NHSRIC Jun 16

Holoclar Limbal stem cell deficiency due to ocular burns NHSRIC Jul 15

Hydrocortisone (Plenadren) Adrenal insufficiency in adults SMC Dec 16

Ibrutinib Waldenström’s macroglobulinaemia – untreated or previously treated patients, in combination with rituximab NHSRIC Sep 16

Ibrutinib Chronic lymphocytic leukaemia or small lymphocytic lymphoma in combination with bendamustine and rituximab – second-line NHSRIC Jan 16

Ibrutinib Diffuse large B-cell lymphoma with R-CHOP – first-line NHSRIC Jan 16

Ibrutinib Relapsed and refractory marginal zone lymphoma – second or subsequent line NHSRIC Jan 16

Ibrutinib Previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation NICE Jan 17

Ibrutinib Previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation SMC Aug 16

Ibrutinib Waldenström’s macroglobulinaemia NICE due Mar 17 (In production)

Ibrutinib Waldenström’s macroglobulinaemia NHSRIC Apr 15

Ibrutinib Mantle cell lymphoma in adults, relapsed or refractory AWMSG due TBC (In production)

Ibrutinib Mantle cell lymphoma in adults, relapsed or refractory NICE due Dec 16 (In production – overdue)

Ibrutinib Mantle cell lymphoma in adults, relapsed or refractory SMC Aug 16

Ibrutinib Newly-diagnosed chronic lymphocytic leukaemia – first-line NHSRIC Oct 14

Ibrutinib Newly-diagnosed chronic lymphocytic leukaemia – first-line AWMSG due TBC (In production)

Idalopirdine Alzheimer’s disease as an adjunct to acetylcholinesterase inhibitor therapy NHSRIC Oct 14

Idebenone Visual impairment in adolescent and adult patients with Leber's Hereditary Optic Neuropathy SMC due May 17 (In production)

Idebenone Duchenne muscular dystrophy – first-line NHSRIC Jan 16

In combination with ofatumumab for chronic lymphocytic leukaemia in adults who have received at least one prior therapy, or first line in the presence of 17p
Idelalisib SMC Dec 16
deletion or TP53 mutation in patients not eligible for any other therapies

Idelalisib In combination with bendamustine and rituximab for indolent non-Hodgkin lymphoma – second-line NHSRIC Mar 16

Idelalisib Chronic lymphocytic leukaemia – first-line with bendamustine and rituximab NHSRIC Oct 15

Idelalisib Relapsed chronic lymphocytic leukaemia in combination with bendamustine and rituximab NHSRIC Dec 14

Idelalisib Relapsed chronic lymphocytic leukaemia with ofatumumab NHSRIC Mar 14

Idelalisib Follicular lymphoma that is refractory to two prior lines of treatment SMC May 15

Idelalisib Follicular lymphoma that is refractory to two prior lines of treatment NICE Dec 14

Idelalisib Chronic lymphocytic leukaemia with rituximab NICE Oct 15

Idelalisib Chronic lymphocytic leukaemia with rituximab SMC Mar 15

Idarucizumab Reversal of anticoagulation due to treatment with dabigatran – first-line SMC Sep 16

Idarucizumab Reversal of anticoagulation due to treatment with dabigatran – first-line NICE-ES May 16

Idarucizumab Reversal of anticoagulation due to treatment with dabigatran – first-line LMEN Feb 16

Idarucizumab Reversal of anticoagulation due to treatment with dabigatran – first-line RDTC Dec 15

Idarucizumab Reversal of anticoagulation due to treatment with dabigatran – first-line NHSRIC Feb 15

Idursulfase Hunter syndrome (mucopolysaccharidosis type II) NHSRIC Apr 16

IMA-901 Locally advanced or metastatic renal cell carcinoma ─ first-line NHSRIC Jan 16

Imatinib Gastrointestinal stromal tumours in adults – adjuvant treatment NICE Nov 14

Imatinib Gastrointestinal stromal tumours in adults – adjuvant treatment AWMSG Jul 14

Imatinib Adults with untreated Philadelphia chromosome positive chronic myelogenous leukaemia in the chronic phase NICE Dec 16

Imatinib High-dose in adults with chronic-, accelerated- or blast-phase chronic myeloid leukaemia with resistance or intolerance to prior imatinib NICE Dec 16

Infliximab Extra-pulmonary sarcoidosis NICE-ES Jan 17

Infliximab Pulmonary sarcoidosis NICE-ES Dec 16

Infliximab Moderate-to-severe active ulcerative colitis in adults, second-line NICE Feb 15

Infliximab Moderate-to-severe active ulcerative colitis in adults, second-line NTAG Dec 14 Appraisal report

Infliximab Moderate-to-severe active ulcerative colitis in adults, second-line NTAG Dec 14 Recommendation

Infliximab Moderate-to-severe active ulcerative colitis in adults, second-line SMC May 14 (Resubmission)

Infliximab Ankylosing spondylitis and axial spondyloarthritis (non-radiographic) NICE Feb 16

Infliximab Psoriatic arthritis, sequential use of TNF inhibitors NTAG Sep 15 Appraisal report

Infliximab Psoriatic arthritis, sequential use of TNF inhibitors NTAG Sep 15 Recommendation

Infliximab Rheumatoid arthritis NICE Jan 16 (Update)

Rheumatoid arthritis, adult Crohn’s disease, paediatric Crohn’s disease, ulcerative colitis, paediatric ulcerative colitis, psoriatic arthritis, psoriasis, ankylosing
Infliximab biosimilars (Inflectra and Remsima) NTAG Sep 15 (update) Appraisal report
spondylitis
Rheumatoid arthritis, adult Crohn’s disease, paediatric Crohn’s disease, ulcerative colitis, paediatric ulcerative colitis, psoriatic arthritis, psoriasis, ankylosing
Infliximab biosimilars (Inflectra and Remsima) NTAG Sep 15 (update) Recommendation
spondylitis
Rheumatoid arthritis, adult Crohn’s disease, paediatric Crohn’s disease, ulcerative colitis, paediatric ulcerative colitis, psoriatic arthritis, psoriasis, ankylosing
Infliximab biosimilars (Inflectra and Remsima) SMC Mar 15 (Inflectra)
spondylitis
Rheumatoid arthritis, adult Crohn’s disease, paediatric Crohn’s disease, ulcerative colitis, paediatric ulcerative colitis, psoriatic arthritis, psoriasis, ankylosing
Infliximab biosimilars (Inflectra and Remsima) SMC Mar 15 (Remsima)
spondylitis
Rheumatoid arthritis, adult Crohn’s disease, paediatric Crohn’s disease, ulcerative colitis, paediatric ulcerative colitis, psoriatic arthritis, psoriasis, ankylosing
Infliximab biosimilars (Inflectra and Remsima) AWMSG Mar 15 (Inflectra)
spondylitis
Rheumatoid arthritis, adult Crohn’s disease, paediatric Crohn’s disease, ulcerative colitis, paediatric ulcerative colitis, psoriatic arthritis, psoriasis, ankylosing
Infliximab biosimilars (Inflectra and Remsima) AWMSG Mar 15 (Remsima)
spondylitis
Rheumatoid arthritis, adult Crohn’s disease, paediatric Crohn’s disease, ulcerative colitis, paediatric ulcerative colitis, psoriatic arthritis, psoriasis, ankylosing
Infliximab biosimilars (Inflectra and Remsima) UKMi Feb 15
spondylitis

Infliximab biosimilars (Inflectra and Remsima) Ankylosing spondylitis and axial spondyloarthritis (non-radiographic) NICE Feb 16

Inotuzumab ozogamicin Acute lymphoblastic leukaemia – second or subsequent line NHSRIC Mar 14

Insulin aspart (Fiasp) Type 1 or type 2 diabetes mellitus in adults in combination with intermediate or long acting insulin SMC due Apr 17 (In production)

Insulin degludec Diabetes mellitus in adults, adolescents and children from the age of one year AWMSG Oct 16

Insulin degludec Diabetes mellitus in adults, adolescents and children from the age of one year SMC May 15

Insulin degludec Diabetes mellitus SMC Aug 16 (Resubmission)

Insulin degludec Diabetes mellitus AWMSG Jul 14

Insulin degludec Diabetes mellitus SMC Mar 14 (Resubmission)

Insulin detemir Diabetes mellitus in adults, adolescents and children aged 1 year and above SMC Mar 16

Insulin glargine (Toujeo) Type 1 or 2 diabetes mellitus in adults aged 18 years and above NICE-ES Dec 15 (Type 2 diabetes)

Insulin glargine (Toujeo) Type 1 or 2 diabetes mellitus in adults aged 18 years and above NTAG Nov 15 Appraisal report
Insulin glargine (Toujeo) Type 1 or 2 diabetes mellitus in adults aged 18 years and above NTAG Nov 15 Recommendation

Insulin glargine (Toujeo) Type 1 or 2 diabetes mellitus in adults aged 18 years and above NICE-ES Oct 15 (Type 1 diabetes)

Insulin glargine (Toujeo) Type 1 or 2 diabetes mellitus in adults aged 18 years and above UKMi Oct 15

Insulin glargine (Toujeo) Type 1 or 2 diabetes mellitus in adults aged 18 years and above SMC Sep 15

Insulin glargine (Toujeo) Type 1 or 2 diabetes mellitus in adults aged 18 years and above MTRAC Jul 15

Insulin glargine (Abasaglar) Diabetes mellitus in adults, adolescents and children aged 2 years and older AWMSG Dec 15

Insulin glargine (Abasaglar) Diabetes mellitus in adults, adolescents and children aged 2 years and older NICE-ES Dec 15

Insulin glargine (Abasaglar) Diabetes mellitus in adults, adolescents and children aged 2 years and older NTAG Nov 15 Appraisal report

Insulin glargine (Abasaglar) Diabetes mellitus in adults, adolescents and children aged 2 years and older NTAG Nov 15 Recommendation

Insulin glargine (Abasaglar) Diabetes mellitus in adults, adolescents and children aged 2 years and older UKMi Oct 15

Insulin glargine (Abasaglar) Diabetes mellitus in adults, adolescents and children aged 2 years and older LMEN Oct 15

Insulin glargine (Abasaglar) Diabetes mellitus in adults, adolescents and children aged 2 years and older MTRAC Jul 15

Intepirdine Alzheimer’s disease – add on therapy NHSRIC Nov 16

Interferon beta-1a (Traumakine) Acute respiratory distress syndrome – first-line NHSRIC May 14

Invicorp (aviptadil and phentolamine) Symptomatic treatment of erectile dysfunction in adults due to neurogenic, vasulogenic, psychogenic, or mixed aetiology AWMSG due TBC (In production)

Ipilimumab Advanced or metastatic renal cell carcinoma – first-line in combination with nivolumab NHSRIC Sep 16

Ipilimumab Small cell lung cancer – first-line, in combination with etoposide and platinum therapy NHSRIC Apr 15

Ipilimumab Non-small cell lung cancer, stage IV or recurrent, with paclitaxel and carboplatin NHSRIC Feb 15

Ipilimumab Prostate cancer, chemotherapy-naïve, hormone-relapsed metastatic NHSRIC Feb 15

Ipilimumab Metastatic hormone-relapsed prostate cancer following docetaxel treatment and radiotherapy NHSRIC Dec 14

Ipilimumab Advanced melanoma in previously untreated adults SMC Nov 14

Ipilimumab Advanced melanoma in previously untreated adults NICE Jul 14

Metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil and leucovorin in patients who have progressed following gemcitabine based
Pegylated liposomal irinotecan (Onivyde) SMC due Feb 17 (In production)
therapy

HA-irinotecan Metastatic colorectal cancer – second and third-line NHSRIC Mar 14

Irinotecan-eluting beads (DC Bead, DC Bead M1 and DC

Liver metastases secondary to colorectal cancer NHSRIC Mar 16
Bead Lumi)
SMC due Feb 17 (In production –
Iron (lll) isomaltoside 1000 (Diafer) Treatment of iron deficiency in adults with chronic kidney disease on dialysis, when oral iron preparations are ineffective or cannot be used.
resubmission)
Iron (lll) isomaltoside 1000 (Diafer) Treatment of iron deficiency in adults with chronic kidney disease on dialysis, when oral iron preparations are ineffective or cannot be used. SMC Sep 16

Isavuconazole Invasive aspergillosis and mucormycosis in adults AWMSG Jan 17

Isavuconazole Invasive aspergillosis and mucormycosis in adults SMC Apr 16

Ivacaftor Patients with cystic fibrosis aged 18 years and older who have an R117H mutation in the CFTR gene SMC Dec 16

Ivacaftor Cystic fibrosis in patients (aged 2 to less than 6 years old) with class III non-G551D gating mutations AWMSG Jan 17

Ivacaftor Cystic fibrosis in patients with class III non-G551D gating mutations SMC May 16

Ivacaftor Cystic fibrosis in patients with class III non-G551D gating mutations AWMSG Jan 16

Ivacaftor Cystic fibrosis in patients with class III non-G551D gating mutations NHSRIC Aug 14

Ivacaftor and tezacaftor Cystic fibrosis with a homozygous or heterozygous F508del CFTR mutation NHSRIC Nov 16

Ivermectin Resistant scabies NICE-ES Mar 14

Ivermectin 1% topical cream Papulopustular rosacea AWMSG Apr 16

Ivermectin 1% topical cream Papulopustular rosacea NICE-ES Jan 16

Ivermectin 1% topical cream Papulopustular rosacea SMC Dec 15

Ivermectin 1% topical cream Papulopustular rosacea RDTC Oct 15

Ivermectin 1% topical cream Papulopustular rosacea NHSRIC Aug 14

Ixazomib Multiple myeloma – first-line in combination with lenalidomide and dexamethasone NHSRIC Nov 16

Ixazomib In combination with oral dexamethasone for relapsed or refractory systemic light chain amyloidosis NHSRIC Mar 14

Ixazomib Relapsed and/or refractory multiple myeloma NHSRIC Mar 14

Ixekizumab Psoriatic arthritis – second line NHSRIC Jan 17

Ixekizumab Moderate-to-severe chronic plaque psoriasis NICE due Apr 17 (in production)

Ixekizumab Moderate-to-severe chronic plaque psoriasis SMC due Apr 17 (In production)

Ixekizumab Moderate-to-severe chronic plaque psoriasis NHSRIC Apr 15

Jentadueto (linagliptin and metformin) Type 2 diabetes mellitus SMC Jun 15

Jentadueto (linagliptin and metformin) Type 2 diabetes mellitus AWMSG Aug 14

Ketamine (oral) Chronic pain NICE-ES Feb 14

Ketoconazole Endogenous Cushing’s syndrome in adults and adolescents aged over 12 years SMC Sep 15
KRN23 X-linked hypophosphataemia in children aged 5-12 years – first-line NHSRIC Jun 16

KTE-C19 Diffuse large B-cell lymphoma and related disorders – refractory disease or relapsed post autologous stem cell transplant NHSRIC Aug 16

Latanoprostene bunod Open-angle glaucoma or ocular hypertension – first-line NHSRIC Mar 16

Lanreotide Unresectable, locally advanced or metastatic gastro-enteropancreatic neuroendocrine tumours NICE due TBC (In production)

Lanreotide Unresectable, locally advanced or metastatic gastro-enteropancreatic neuroendocrine tumours AWMSG Dec 15

Lanreotide Unresectable, locally advanced or metastatic gastro-enteropancreatic neuroendocrine tumours NHSRIC Dec 14

Lapatinib Early HER2-positive breast cancer, neoadjuvant therapy in combination with trastuzumab NHSRIC May 14

Laquinimod Multiple sclerosis - relapsing-remitting NICE due TBC (In production)

Lebrikizumab Severe asthma – second-line NHSRIC Mar 16

Lefitolimod Extensive small cell lung cancer – maintenance therapy NHSRIC May 16

Lenalidomide Mantle cell lymphoma – relapsed or refractory SMC Nov 16

Lenalidomide Previously untreated multiple myeloma in adults who are not eligible for transplant, in combination with dexamethasone AWMSG Jul 16

Lenalidomide Previously untreated multiple myeloma in adults who are not eligible for transplant, in combination with dexamethasone SMC Dec 15

Lenalidomide Multiple myeloma – second-line NICE due TBC (In production)

Lenalidomide Multiple myeloma – second-line SMC Apr 14 (Resubmission)

Lenalidomide Myelodysplastic syndromes NICE Sep 14

Lenalidomide Myelodysplastic syndromes SMC Mar 14

Lenvatinib (Lenvima) Treatment of adults with progressive, locally advanced or metastatic, differentiated thyroid carcinoma, refractory to radioactive iodine SMC Oct 16

Lenvatinib Unresectable hepatocellular carcinoma – first-line NHSRIC May 16

Lenvatinib (Kisplyx) Advanced or metastatic renal cell carcinoma in combination with everolimus – second-line NHSRIC Jan 16

LentiGlobin BB305 Beta-thalassaemia major – first-line NHSRIC Jan 16

Lesinurad Gout MTRAC due TBC (In production)

Lesinurad Gout RDTC Oct 16

Letermovir Prevention of cytomegalovirus infection in sero-positive patients undergoing allogeneic haematopoietic stem cell transplantation NHSRIC May 16

Leuprorelin acetate Neoadjuvant treatment prior to radiotherapy in patients with high risk localised or locally advanced prostate cancer AWMSG Jan 15

Levofloxacin (Quinsair) Chronic pulmonary infections due to Pseudomonas aeruginosa in adults with cystic fibrosis NICE-ES due TBC (In production)
Levofloxacin (Quinsair) Chronic pulmonary infections due to Pseudomonas aeruginosa in adults with cystic fibrosis AWMSG Nov 16

Levofloxacin (Quinsair) Chronic pulmonary infections due to Pseudomonas aeruginosa in adults with cystic fibrosis SMC Aug 16

Levonorgestrel (Levosert) Contraception, particularly for women with heavy menstrual bleeding SMC Jun 15

Levonorgestrel (Upostelle) Emergency contraception within 72 hours of unprotected sexual intercourse SMC Feb 14

Levonorgestrel 13.5mg intrauterine system Up to 3 years’ contraception AWMSG Jul 15

Levonorgestrel 13.5mg intrauterine system Up to 3 years’ contraception SMC Apr 15

Levonorgestrel 13.5mg intrauterine system Up to 3 years’ contraception NICE-ES Jun 14

Levosimendan Severe acute decompensated chronic heart failure – second-line NHSRIC Mar 2014

Lifitegrast Dry eye disease NHSRIC Sep 16

Linaclotide Irritable bowel syndrome with constipation AWMSG Feb 14

Linagliptin Type 2 diabetes SMC May 15 (Resubmission)

Linagliptin Type 2 diabetes MTRAC May 14

Lipegfilgrastim Chemotherapy-induced neutropenia (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) AWMSG Aug 14

Lipegfilgrastim Chemotherapy-induced neutropenia (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) SMC Apr 14
Monotherapy for treatment of adults with type 2 diabetes mellitus to achieve glycaemic control when diet and exercise alone do not provide adequate
Liraglutide SMC Sep 16
glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance or contraindications

Liraglutide Obesity MTRAC Jan 16

Liraglutide Obesity RDTC Oct 15

Liraglutide Type 2 diabetes mellitus in adults MTRAC Jul 16

Liraglutide Type 2 diabetes mellitus in adults SMC May 15

Lisdexamfetamine Attention deficit hyperactivity disorder in adults LMEN Sep 15

Lisdexamfetamine Attention deficit hyperactivity disorder in adults AWMSG Oct 15

Lisdexamfetamine Attention deficit hyperactivity disorder in adults SMC Sep 15

Lixisenatide Type 2 diabetes MTRAC Jul 16

Lomitapide Homozygous familial hypercholesterolaemia in adults SMC Feb 14

Lonsurf (trifluridine and tipiracil hydrochloride) Previously treated metastatic colorectal cancer SMC due Feb 17 (In production)

Lonsurf (trifluridine and tipiracil hydrochloride) Previously treated metastatic colorectal cancer NICE Aug 16
Lopixibat Progressive familial intrahepatic cholestasis in paediatric patients NHSRIC Aug 15

Lubiprostone Constipation SMC Aug 14

Lubiprostone Constipation NICE Jul 14

Lubiprostone Constipation RDTC Mar 14

Lurasidone Schizophrenia NTAG Apr15 Appraisal report

Lurasidone Schizophrenia NTAG Apr15 Recommendation

Lurasidone Schizophrenia AWMSG Mar 15

Lurasidone Schizophrenia LMEN Mar 15

Lurasidone Schizophrenia SMC Oct 14

Lurasidone Schizophrenia NICE-ES Sep 14

Lusutrombopag Severe thrombocytopenia in patients with chronic liver disease undergoing an elective invasive procedure NHSRIC Dec 16

Lutetium-177 Inoperable gastroenteropancreatic neuroendocrine tumours NHSRIC May 14

Macitentan Long-term treatment of adults with pulmonary arterial hypertension (WHO Functional Class II to III) AWMSG Jan 16

Macitentan Long-term treatment of adults with pulmonary arterial hypertension (WHO Functional Class II to III) SMC Apr 14

Magnesium aspartate dihydrate Treatment and prevention of magnesium deficiency AWMSG Sep 15

Magnesium aspartate dihydrate Treatment and prevention of magnesium deficiency SMC Jun 15

MABp1 (Xilonix) Metastatic colorectal cancer NICE due Feb 17 (In production)

MABp1 (Xilonix) Metastatic colorectal cancer NHSRIC Aug 15

Masitinib Relapsed or refractory peripheral T-cell lymphoma NHSRIC May 16

Masitinib Advanced or metastatic malignant melanoma with a c-kit juxtamembrane mutation NHSRIC Mar 16

Masitinib Crohn’s disease, in patients intolerant of, or with an unsatisfactory response to, immunosuppressive drugs and/or TNF-inhibitors NHSRIC Aug 15

Masitinib Primary and relapse-free secondary progressive multiple sclerosis – first-line NHSRIC Aug 15

Masitinib Rheumatoid arthritis – second and subsequent line NHSRIC Aug 15

Masitinib Amyotrophic lateral sclerosis – add-on therapy to riluzole NHSRIC Apr 15

Medabon (mifepristone and misoprostol) Termination of developing intra-uterine pregnancy of up to 63 days of amenorrhoea SMC Nov 14

Memantine Alzheimer’s disease NICE May 16

Mepolizumab Chronic obstructive pulmonary disease with eosinophilic bronchitis – add on therapy NHSRIC Aug 16

Mepolizumab Relapsed or refractory eosinophilic granulomatosis with polyangiitis – second-line add on therapy NHSRIC Aug 16

Mepolizumab Severe refractory eosinophilic asthma in adults SMC Jun 16

Mepolizumab Severe refractory eosinophilic asthma in adults NICE Jan 17

Mepolizumab Severe refractory eosinophilic asthma in adults NHSRIC May 14

Mereletinib Locally advanced or metastatic, EGFR and T790M mutation positive non-small cell lung cancer – second-line NHSRIC Apr 15

Methoxyflurane Emergency relief of moderate to severe pain NHSRIC Mar 16

Methylnaltrexone Opioid-induced constipation in adults with chronic non-malignant pain NHSRIC Aug 14

Methylphenidate extended release Attention-deficit hyperactivity disorder LMEN May 16

Metreleptin Generalised and partial lipodystrophy NHSRIC May 14

Midodrine Orthostatic hypotension due to autonomic dysfunction AWMSG Nov 15

Midodrine Orthostatic hypotension due to autonomic dysfunction SMC Oct 15

Midodrine Orthostatic hypotension due to autonomic dysfunction NICE-ES Oct 15

Midodrine Orthostatic hypotension due to autonomic dysfunction NHSRIC Jul 15

Midostaurin Newly diagnosed FLT3-mutated acute myeloid leukaemia – first-line NHSRIC Feb 14

Migalastat Fabry disease NICE due Jan 17 (In production-overdue)

Migalastat Fabry disease SMC Nov 16

Migalastat Fabry disease NHSRIC Mar 14

Misoprostol pessary Induction of labour AWMSG Aug 16

Misoprostol pessary Induction of labour SMC Oct 14

Misoprostol pessary Induction of labour NICE-ES Mar 14

Mitomycin ophthalmic (Mitosol) Glaucoma surgery NHSRIC Apr 16

MK3682B (uprifosbuvir, ruzasvir and grazoprevir) Hepatitis C infection – first-line NHSRIC Dec 16

Modafinil Excessive daytime sleepiness in Parkinson's disease NICE-ES Sep 15

Mogamulizumab Relapsed or refractory cutaneous T-cell lymphoma – second- and subsequent-lines NHSRIC Jun 16

Mogamulizumab Adult T-cell leukaemia/lymphoma – second and subsequent line NHSRIC Aug 14
Molgramostim inhalation Autoimmune pulmonary alveolar proteinosis NHSRIC Sep 16

Momelotinib Myelofibrosis NHSRIC Aug 16

Mometasone furoate Symptoms of seasonal allergic or perennial rhinitis in children aged 3 to 6 years AWMSG Dec 15

Moxetumomab pasudotox Stage III or IV hairy cell leukaemia – third-line NHSRIC Dec 16

MUC-1 (CVac) Stage III or IV epithelial ovarian cancer – first or second remission after surgery and/or chemotherapy NHSRIC Nov 16

Multivitamins and minerals Age-Related Macular Degeneration NTAG Jun 14 Appraisal report

Multivitamins and minerals Age-Related Macular Degeneration NTAG Jun 14 Recommendation

Mycophenolate Systemic lupus erythematosus NICE-ES Nov 14

Mycophenolate Scleroderma NICE-ES Jul 14

Mysimba (naltrexone and bupropion) Weight management in adults MTRAC Jan 16

Mysimba (naltrexone and bupropion) Weight management in adults RDTC Sep 15

Mysimba (naltrexone and bupropion) Weight management in adults LMEN Jun 15

Naldemedine Opioid-induced constipation in adults NHSRIC Jun 16

Nalmefene Alcohol dependence NICE Nov 14

Nalmefene Alcohol dependence NTAG Feb 14 Appraisal report

Nalmefene Alcohol dependence NTAG Feb 14 Recommendation

Nalmefene Alcohol dependence AWMSG Feb 14

Naloxegol Opioid-induced constipation SMC Dec 15

Naloxegol Opioid-induced constipation NICE Jul 15

Naloxegol Opioid-induced constipation RDTC Apr 15

Naloxone nasal spray Suspected or known opioid overdose NHSRIC Dec 16

Naloxone nasal spray Opioid overdose NHSRIC May 16

Naloxone (pre-filled syringe) Emergency opiate reversal in non-medical settings UKMI Mar 16

Napabucasin In combination with paclitaxel for gastric and gastroesophageal junction adenocarcinoma – second-line NHSRIC Aug 16

Pain relief in patients with rheumatoid arthritis, osteoarthritis or ankylosing spondylitis. Treatment of pain associated with acute gout. Treatment of symptoms of
Naproxen (Stirlescent) SMC Jun 16
dysmenorrhoea and acute musculoskeletal conditions

Natalizumab Secondary progressive multiple sclerosis NHSRIC Apr 15

Natalizumab Highly active relapsing remitting multiple sclerosis in adults – second-line SMC Jun 14

NBTXR-3 Advanced soft tissue sarcoma – first-line NHSRIC Mar 16

Necitumumab Advanced or metastatic non-small cell lung cancer in combination with gemcitabine and cisplatin – first-line NICE Sep 16

Necitumumab Advanced or metastatic non-small cell lung cancer in combination with gemcitabine and cisplatin – first-line SMC Aug 16

Necitumumab Advanced or metastatic non-small cell lung cancer in combination with gemcitabine and cisplatin – first-line NHSRIC Feb 14

Nefopam Persistent pain unresponsive to other non-opioid analgesics RDTC Jan 15

Nepafenac Reduction in the risk of operative macular oedema associated with caract surgery in diabetic patients SMC due Apr 17 (In production)

Neratinib Early stage HER2-positive breast cancer after adjuvant treatment with trastuzumab NHSRIC Aug 16

Neratinib Advanced for metastatic HER2-positive breast cancer, with capecitabine – third-line NHSRIC Jul 15

Neratinib HER2-positive early breast cancer NHSRIC Aug 14

Netarsudil Open-angle glaucoma or ocular hypertension NHSRIC Apr 16

Nilotinib Adults with untreated Philadelphia chromosome positive chronic myeloid leukaemia in the chronic phase NICE Dec 16

Nilotinib Adults with chronic- or accelerated-phase chronic myeloid leukaemia with resistance or intolerance to imatinib NICE Dec 16

Nilvadipine Mild to moderate Alzheimer's disease – first- or second-line NHSRIC Aug 16

Nintedanib (Vargatef) Metastatic colorectal cancer – second- and subsequent-line NHSRIC Mar 16

Nintedanib (Vargatef) Locally advanced, metastatic or recurrent non-small cell lung adenocarcinoma – second-line NICE Jul 15

Nintedanib (Vargatef) Locally advanced, metastatic or recurrent non-small cell lung adenocarcinoma – second-line SMC Apr 15

Nintedanib (Ofev) Idiopathic pulmonary fibrosis NICE Jan 16

Nintedanib (Ofev) Idiopathic pulmonary fibrosis SMC Oct 15

Niraparib HER2-negative, germline BRCA mutated, locally advanced or metastatic breast cancer NHSRIC Oct 14

Niraparib High grade serous, platinum-sensitive ovarian cancer – second-line maintenance therapy NHSRIC Aug 14

Nivolumab Small-cell lung cancer – second-line NHSRIC Nov 16

Nivolumab Advanced or metastatic renal cell carcinoma – first-line in combination with ipilimumab NHSRIC Sep 16

Nivolumab Gastric and gastroesophageal junction adenocarcinoma NHSRIC Sep 16

Nivolumab Locally advanced or metastatic non-squamous non-small cell lung cancer – second-line SMC Oct 16

Nivolumab Stage IV or recurrent non-small cell lung cancer – first-line NHSRIC Mar 16
Nivolumab Stage IV or recurrent PD-L1 positive non-small cell lung cancer – first-line NHSRIC Mar 16

Nivolumab Metastatic or unresectable urothelial bladder cancer – second-line NHSRIC Jan 16

Nivolumab Follicular non-Hodgkin lymphoma ─ third-line NHSRIC Jan 16

Nivolumab Recurrent glioblastoma – second-line NHSRIC Oct 15

Nivolumab Hodgkin lymphoma in brentuximab treated patients – second-line NHSRIC Oct 15

Nivolumab Hodgkin lymphoma in brentuximab naïve patients – second-line NHSRIC Oct 15

Nivolumab Recurrent or metastatic squamous cell carcinoma of the head and neck – second-line NHSRIC Oct 15

Nivolumab Diffuse large B cell lymphoma –second-line NHSRIC Oct 15

Nivolumab Advanced melanoma – monotherapy SMC Aug 16 (Resubmission)

Nivolumab Advanced melanoma – monotherapy SMC Mar 16

Nivolumab Advanced melanoma – monotherapy NICE Feb 16

Nivolumab Advanced melanoma – monotherapy NHSRIC Dec 14 (BRAF V600 mutation-positive – first-line)

Nivolumab Advanced melanoma – monotherapy NHSRIC Dec 14 (BRAF V600 mutation-negative – first-line)

Nivolumab Advanced melanoma – monotherapy NHSRIC Dec 14 (Second – or third-line)

Nivolumab Advanced or metastatic renal cell NICE Nov 16

Nivolumab Carcinoma – previously-treated SMC Nov 16

Nivolumab Advanced or metastatic clear-cell renal cell carcinoma – second- or third-line NHSRIC Dec 14

Nivolumab Advanced melanoma – first-line with ipilimumab SMC Nov 16

Nivolumab Advanced melanoma – first-line with ipilimumab NICE Jul 16

Nivolumab Advanced melanoma – first-line with ipilimumab NHSRIC Dec 14

Nivolumab Locally advanced or metastatic squamous non-small cell lung cancer after prior chemotherapy in adults SMC Jul 16

Nusinersen Paediatric-onset spinal muscular atrophy – first-line NHSRIC Apr 16

Primary biliary cirrhosis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable
Obeticholic acid SMC due May 17 (In production)
to tolerate UDCA.

Obinutuzumab Indolent non-Hodgkin lymphoma, in combination with chemotherapy – first-line NHSRIC Aug 15

Obinutuzumab Chronic lymphocytic leukaemia in combination with bendamustine ─ first-line NHSRIC Jan 16

Obinutuzumab Chronic lymphocytic leukaemia in adults, in combination with chlorambucil – first-line NICE Jun 15
Obinutuzumab Chronic lymphocytic leukaemia in adults, in combination with chlorambucil – first-line SMC Dec 14

Obinutuzumab Rituximab-refractory indolent non-Hodgkin’s lymphoma, in combination with bendamustine – second-line SMC due Feb 17 (In production)

Obinutuzumab Rituximab-refractory indolent non-Hodgkin’s lymphoma, in combination with bendamustine – second-line NICE due Jan 17 (In production-overdue)

Obinutuzumab Rituximab-refractory indolent non-Hodgkin’s lymphoma, in combination with bendamustine – second-line NHSRIC Mar 14

Obinutuzumab CD20-positive diffuse large B-cell lymphoma, in combination with CHOP – first-line NHSRIC Mar 14

Ocrelizumab Relapsing-remitting multiple sclerosis NHSRIC Aug 14

Ocrelizumab Primary progressive multiple sclerosis NHSRIC Aug 14

Ocriplasmin Vitreomacular traction SMC Aug 14 (Resubmission)

Adults and adolescents (12 years and older with body weight ≥35 kg) with HIV 1, without known mutations associated with resistance to NNRTI class, tenofovir
Odefsey (rilpivirine / emtricitabine / tenofovir alafenamide) AWMSG Nov 16
or emtricitabine and with a viral load ≤ 100,000 HIV 1 RNA copies/mL
Adults and adolescents (12 years and older with body weight ≥35 kg) with HIV 1, without known mutations associated with resistance to NNRTI class, tenofovir
Odefsey (rilpivirine / emtricitabine / tenofovir alafenamide) SMC Oct 16
or emtricitabine and with a viral load ≤ 100,000 HIV 1 RNA copies/mL

Ofatumumab Refractory follicular lymphoma – third-line in combination with bendamustine NHSRIC Jun 16

Ofatumumab Chronic lymphocytic leukaemia, in combination with chlorambucil or bendamustine NICE Jun 15

Ofatumumab Chronic lymphocytic leukaemia, in combination with chlorambucil or bendamustine SMC May 15

Olanzapine (ZypAdhera) Maintenance treatment of schizophrenia, in adults sufficiently stabilised with oral olanzapine during acute treatment AWMSG Jul 16

Olaparib High risk advanced ovarian cancer with BRCA germline mutations – maintenance therapy NHSRIC Jan 17

Olaparib Metastatic breast cancer with germline BRCA mutation – second-line NHSRIC Mar 16

Olaparib Relapsed platinum-sensitive ovarian cancer SMC Nov 16 (Resubmission)

Olaparib Relapsed platinum-sensitive ovarian cancer NICE Jan 16

Olaparib Relapsed platinum-sensitive ovarian cancer SMC Jul 15

Olaratumab Advanced soft tissue sarcoma in combination with doxorubicin NHSRIC Oct 15

Olodaterol (Striverdi Respimat) Chronic obstructive pulmonary disease NICE-ES Feb 15

Olodaterol (Striverdi Respimat) Chronic obstructive pulmonary disease AWMSG Jan 15

Olodaterol (Striverdi Respimat) Chronic obstructive pulmonary disease SMC Jan 15 (Resubmission)

Omalizumab Chronic spontaneous urticaria in patients with inadequate response to antihistamines NICE Jun 15

Omalizumab Chronic spontaneous urticaria in patients with inadequate response to antihistamines SMC Jan 15

Onartuzumab Metastatic Met-positive gastric or gastro-oesophageal junction cancer NHSRIC Mar 14

Ondansetron Prevention of nausea and vomiting in children with gastroenteritis NICE-ES Oct 14

Opicapone Adjunctive therapy in adult patients with Parkinson’s disease and motor fluctuations NICE-ES due Feb 17 (In production)

Orkambi (lumacaftor and ivacaftor) Cystic fibrosis in patients aged 12 years or older who are homozygous for the F508del mutation in the CFTR gene NICE Jul 16

Orkambi (lumacaftor and ivacaftor) Cystic fibrosis in patients aged 12 years or older who are homozygous for the F508del mutation in the CFTR gene SMC May 16

Oritavancin Treatment of acute bacterial skin and skin structure infections in adults SMC due TBC (In production)

Oseltamivir Influenza in children <1 year of age AWMSG Apr 16

Oseltamivir Influenza in children <1 year of age SMC Mar 16

Osimertinib Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer SMC due Feb 17 (In production)

Osimertinib Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer NICE Oct 16

Otovent Auto-inflation device for glue ear UKMi Nov 14

Ozanimod Relapsing remitting multiple sclerosis NHSRIC Sep 16

Paclitaxel Ovarian cancer – advanced, recurrent NICE Apr 16

Pacritinib Myelofibrosis NHSRIC Feb 14

Padeliporfin Localised prostate cancer – first-line NHSRIC Feb 15

Palbociclib Advanced or metastatic ER-positive/HER2-negative, breast cancer – second-line NHSRIC Jul 15

Palbociclib Advanced ER-positive/HER2-negative breast cancer in post-menopausal women – first-line in combination with letrozole NHSRIC May 14

Paliperidone palmitate Schizophrenia in adults LMEN Sep 16

Paliperidone palmitate Schizophrenia in adults SMC Sep 16

Paliperidone palmitate Schizophrenia in adults NTAG Apr 15 Appraisal report

Paliperidone palmitate Schizophrenia in adults NTAG Apr 15 Recommendation

Paliperidone palmitate Schizophrenia in adults LMEN Mar 15

Palonosetron Prevention of nausea and vomiting associated with moderate and highly emetogenic cancer chemotherapy in patients one month of age and older SMC Aug 15

Panitumumab Wild-type RAS metastatic colorectal cancer – first-line in combination with chemotherapy SMC Jul 15

Panobinostat Multiple myeloma – relapsed and/or refractory, in combination with bortezomib and dexamethasone SMC Feb 16

Panobinostat Multiple myeloma – relapsed and/or refractory, in combination with bortezomib and dexamethasone NICE Jan 16

Pasireotide Acromegaly in adults

AWMSG Jun 16
Pasireotide Acromegaly in adults
SMC Sep 15

Patiromer Hyperkalaemia - first-line NHSRIC Jul 15

Patisiran Polyneuropathy in patients with hereditary transthyretin-related amyloidosis NHSRIC Jan 17

Pegargiminase (ADI-PEG 20) Hepatocellular carcinoma – second-line NHSRIC Apr 16

Pegaspargase Acute lymphoblastic leukaemia SMC Nov 16

Pegaspargase Acute lymphoblastic leukaemia NICE Sep 16

Pegaspargase Acute lymphoblastic leukaemia NHSRIC Feb 15

Peginterferon beta-1a Relapsing-remitting multiple sclerosis AWMSG Jul 15

Peginterferon beta-1a Relapsing-remitting multiple sclerosis SMC Jan 15

Peginterferon lambda-1a Hepatitis C NHSRIC Aug 14

Pegpleranib Wet age-related macular degeneration (AMD) NHSRIC Jan 16

Pegvaliase Hyperphenylalaninaemia in adults with phenylketonuria – first-line NHSRIC Jun 16

Pelareorep Recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer – in combination with paclitaxel NHSRIC Jun 16

Pelareorep Advanced or metastatic pancreatic cancer – first-line NHSRIC Mar 16

Pelareorep Relapsed or refractory multiple myeloma NHSRIC Mar 16

Pelareorep Metastatic or recurrent squamous cell carcinoma of the head and neck, in combination with chemotherapy – second-line NHSRIC Aug 15

Pelareorep Metastatic malignant melanoma, with or without chemotherapy – second-line NHSRIC Aug 15

Pembrolizumab In combination with pemetrexed and platinum chemotherapy for non-small cell lung cancer NHSRIC Jan 17

Pembrolizumab In combination with pomalidomide and dexamethasone for relapsed and refractory multiple myeloma – second- and subsequent-line NHSRIC Dec 16

Pembrolizumab Recurrent or metastatic squamous cell head and neck cancer – first-line NHSRIC Dec 16

Pembrolizumab Locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma – second-line NHSRIC Nov 16

Pembrolizumab Advanced non-small cell lung cancer in adults whose tumours express PD-L1 and who have received at least one prior chemotherapy regimen SMC Jan 17

Pembrolizumab Advanced non-small cell lung cancer in adults whose tumours express PD-L1 and who have received at least one prior chemotherapy regimen NICE Jan 17

Pembrolizumab Locally advanced or metastatic colorectal cancer with high-level microsatellite instability – second-line NHSRIC Jul 16

Pembrolizumab Relapsed or refractory classical Hodgkin lymphoma – third and fourth line NHSRIC Jul 16

Pembrolizumab Platinum-resistant, recurrent or metastatic head and neck cancer NHSRIC Mar 16
Pembrolizumab Advanced or metastatic urothelial cancer – second-line NHSRIC Oct 15

Pembrolizumab PD-L1 strong-positive metastatic non-small cell lung cancer – first-line NHSRIC Aug 15

Pembrolizumab Unresectable or metastatic melanoma in patients not previously treated with ipilimumab SMC Nov 15

Pembrolizumab Unresectable or metastatic melanoma in patients not previously treated with ipilimumab NICE Nov 15

Pembrolizumab Unresectable or metastatic melanoma in patients previously treated with ipilimumab SMC Dec 16 (Resubmission)

Pembrolizumab Unresectable or metastatic melanoma in patients previously treated with ipilimumab SMC Nov 15

Pembrolizumab Unresectable or metastatic melanoma in patients previously treated with ipilimumab NICE Oct 15

Pemetrexed Non-small cell, non-squamous lung cancer – maintenance treatment NICE Aug 16

Pemetrexed Non-small cell, non-squamous lung cancer – maintenance treatment SMC Dec 14

Pemetrexed Non-small cell, non-squamous lung cancer – maintenance treatment NICE Apr 14

Pentosan polysulphate sodium Interstitial cystitis NICE-ES Apr 15

Peramivir Acute uncomplicated influenza in adults NHSRIC Oct 14

Perampanel Adjuvant treatment of primary generalised tonic-clonic seizures SMC Oct 16

Perampanel Adjuvant treatment of primary generalised tonic-clonic seizures NHSRIC Mar 14

Perampanel Partial-onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older MTRAC Jul 16 (Update)

Pertuzumab Metastatic HER2-positive gastric cancer – first-line NHSRIC Sep 16

Pertuzumab With chemotherapy and trastuzumab for HER2-positive early breast cancer – adjuvant therapy NHSRIC Apr 16

With docetaxel and trastuzumab for HER2 positive metastatic or locally recurrent unresectable breast cancer, in patients previously untreated or who have SMC due May 17 (In production-
Pertuzumab
relapsed post adjuvant treatment resubmission)
With docetaxel and trastuzumab for HER2 positive metastatic or locally recurrent unresectable breast cancer, in patients previously untreated or who have
Pertuzumab SMC Nov 14 (Resubmission)
relapsed post adjuvant treatment

Pertuzumab HER2-positive locally advanced, inflammatory or early breast cancer – neo-adjuvant in combination with trastuzumab plus chemotherapy NICE Dec 16

Pertuzumab HER2-positive locally advanced, inflammatory or early breast cancer – neo-adjuvant in combination with trastuzumab plus chemotherapy SMC Dec 16 (Resubmission)

Pertuzumab HER2-positive locally advanced, inflammatory or early breast cancer – neo-adjuvant in combination with trastuzumab plus chemotherapy SMC Mar 16

Pertuzumab HER2-positive locally advanced, inflammatory or early breast cancer – neo-adjuvant in combination with trastuzumab plus chemotherapy NHSRIC Feb 14

Pexiganan Mild foot infection in patients with diabetic foot ulcers NHSRIC Jan 16

Pimavanserin Psychosis associated with Parkinson’s disease – first-line NHSRIC Oct 14

Pirfenidone Idiopathic pulmonary fibrosis NICE due TBC (In production-review)

Pitolisant hydrochloride Narcolepsy with or without cataplexy NICE-ES due Feb 17 (In production)

Pitolisant hydrochloride Obstructive sleep apnoea NHSRIC Mar 16

Pixantrone Non-Hodgkin’s lymphoma – relapsed or refractory SMC Feb 16

Pixantrone Non-Hodgkin’s lymphoma – relapsed or refractory NICE Feb 14

Plazomicin Treatment of multi-drug resistant Gram-negative Enterobacteriaceae infections NHSRIC Dec 16

Plazomicin Complicated urinary tract infection NHSRIC Nov 16

Pliaglis (tetracaine and lidocaine) Local dermal anaesthesia on intact skin prior to dermatological procedures in adults SMC Oct 14

Plitidepsin Relapsed and refractory multiple myeloma – fourth-line NHSRIC Oct 15

Pomalidomide Relapsed and refractory multiple myeloma NICE Jan 17

Pomalidomide Relapsed and refractory multiple myeloma AWMSG Sep 15

Pomalidomide Relapsed and refractory multiple myeloma NICE Mar 15

Pomalidomide Relapsed and refractory multiple myeloma SMC Dec 14 (Resubmission)

Pomalidomide Relapsed and refractory multiple myeloma AWMSG Sep 14

Ponatinib Chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia SMC Apr 15

Ponatinib Chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia AWMSG Jan 15

Posaconazole Fungal infections in adults SMC Jul 15

Posaconazole Fungal infections in adults SMC Oct 14

Prasugrel With percutaneous coronary intervention for treating acute coronary syndrome NICE Jul 14 (Update)

Prednisolone (Pevanti) Suppression of inflammatory and allergic disorders UKMi Jul 16

Pridopidine Huntington’s disease NHSRIC Oct 15

Progesterone (Lutigest) Luteal support as part of an assisted reproductive technology (ART) treatment programme for infertile women. SMC Oct 16

Progesterone (micronsed) (Utrogestan) Supplementation of the luteal phase during Assisted Reproductive Technology cycles SMC due May 17 (In production)

Promethazine Rapid tranquilisation in mental health conditions NICE-ES Mar 14

Prucalopride Chronic constipation in men AWMSG Apr 16

Prucalopride Chronic constipation in men LMEN Dec 15

Prucalopride Chronic constipation in men NHSRIC Oct 14

Quizartinib FLT3-ITD positive acute myeloid leukaemia – second-line NHSRIC Jul 16

Racecadotril Acute diarrhoea in infants (older than three months), children and adults – add on to oral rehydration therapy SMC Aug 14 (Resubmission-infants and children)

Radium-223 dichloride Bone metastases in patients with castration-resistant prostate cancer NICE Sep 16

Radium-223 dichloride Bone metastases in patients with castration-resistant prostate cancer NICE Jan 16

Radium-223 dichloride Bone metastases in patients with castration-resistant prostate cancer SMC Oct 15

Raltegravir HIV-1 infection in adults, adolescents, children, toddlers and infants from the age of four weeks AWMSG Dec 15

Raltegravir HIV-1 infection in adults, adolescents, children, toddlers and infants from the age of four weeks SMC Nov 15 (Chewable tablets)

Raltegravir HIV-1 infection in adults, adolescents, children, toddlers and infants from the age of four weeks SMC Nov 15 (Granules)

Ramipril Symptoms of peripheral arterial disease NICE-ES Jun 15

Ramucirumab Metastatic colorectal cancer – second-line SMC May 16

Ramucirumab Metastatic colorectal cancer – second-line NHSRIC Dec 14

Ramucirumab Locally advanced or metastatic non-small cell lung cancer – second-line, in combination with docetaxel NICE Aug 16

Ramucirumab Locally advanced or metastatic non-small cell lung cancer – second-line, in combination with docetaxel SMC Jun 16

Ramucirumab Locally advanced or metastatic non-small cell lung cancer – second-line, in combination with docetaxel NHSRIC Dec 14

Ramucirumab Advanced gastric cancer and gastro-oesophageal junction adenocarcinoma after prior chemotherapy SMC Jul 16

Ramucirumab Advanced gastric cancer and gastro-oesophageal junction adenocarcinoma after prior chemotherapy NICE Jan 16

Ramucirumab Advanced gastric cancer and gastro-oesophageal junction adenocarcinoma after prior chemotherapy NHSRIC Mar 14 (with paclitaxel)

Ranibizumab Choroidal neovascularisation and macular oedema NHSRIC Feb 15

Ranibizumab Age-related macular oedema LMEN Feb 15

Ranibizumab Age-related macular oedema LMEN Jan 15

Ranibizumab Macular oedema secondary to retinal vein occlusion NTAG Feb 14

Ranibizumab biosimilar (PF582) Wet age-related macular oedema, diabetic macular oedema and retinal oedema LMEN Dec 15

Regorafenib Metastatic colorectal cancer, in adults previously treated with, or who are not considered candidates for, available therapies SMC Nov 15

Regorafenib Hepatocellular carcinoma – second-line NHSRIC Oct 15

Regorafenib Unresectable or metastatic gastrointestinal stromal tumours after imatinib and sunitinib AWMSG Jul 15

Regorafenib Unresectable or metastatic gastrointestinal stromal tumours after imatinib and sunitinib SMC Apr 15
Relebactam Drug resistant Gram-negative infections in combination with imipenem and cilastatin NHSRIC Jul 16

Relvar Ellipta (fluticasone furoate and vilanterol) Asthma MTRAC Nov 15

Relvar Ellipta (fluticasone furoate and vilanterol) Asthma UKMi Jan 15

Relvar Ellipta (fluticasone furoate and vilanterol) Asthma AWMSG Aug 14

Relvar Ellipta (fluticasone furoate and vilanterol) Asthma SMC Jun 14

Relvar Ellipta (fluticasone furoate and vilanterol) Asthma NICE-ES Mar 14

Relvar Ellipta (fluticasone furoate and vilanterol) Chronic obstructive pulmonary disease MTRAC Jan 15

Relvar Ellipta (fluticasone furoate and vilanterol) Chronic obstructive pulmonary disease MTRAC Jan 15

Relvar Ellipta (fluticasone furoate and vilanterol) Chronic obstructive pulmonary disease UKMi Jan 15

Relvar Ellipta (fluticasone furoate and vilanterol) Chronic obstructive pulmonary disease AWMSG May 14

Relvar Ellipta (fluticasone furoate and vilanterol) Graft versus host disease in paediatric patients – second-line SMC Apr 14

Remestemcel-L Steroid-refractory acute graft versus host disease – second-line NHSRIC Apr 16

Remestemcel-L Prevention of delayed graft function in pancreatic islet transplantation for type 1 diabetes mellitus NHSRIC Oct 15

Reparixin Eosinophilic asthma NHSRIC May 16

Reslizumab Eosinophilic asthma SMC due May 17 (In production)

Reslizumab Eosinophilic asthma NICE due Apr 17 (In production)

Reslizumab Late-onset Pompe disease NHSRIC Apr 15

Reveglucosidase alfa HIV-1 infection in patients aged at least 18 years NHSRIC Aug 16

Rezolsta (darunavir and cobicistat) HIV-1 infection in patients aged at least 18 years AWMSG Sep 15

Rezolsta (darunavir and cobicistat) Neurotrophic keratopathy SMC Aug 15

RGN-259 Neurotrophic keratitis – first-line NHSRIC May 16

rhNGF Hypoparathyroidism – adjunctive therapy NHSRIC Oct 15

rhPTH (Natpar) Advanced hormone-receptor positive, HER2-negative breast cancer in premenopausal women – first-line NHSRIC Mar 16

Ribociclib Advanced hormone receptor positive, HER2 negative breast cancer – first-line NHSRIC Jul 16

Ribociclib Reduction in recurrence of overt hepatic encephalopathy in adults NHSRIC Oct 15

Rifaxamin Reduction in recurrence of overt hepatic encephalopathy in adults NICE Mar 15

Rifaxamin Higher risk myelodysplastic syndromes – second- and subsequent-line NICE-ES Mar 14

Rigosertib Treatment of HIV‑1 infection in treatment‑naïve patients 12 years of age and older with a viral load ≤100,000 HIV ‑1 RNA copies/ml NHSRIC May 14

Rilpivirine hydrochloride Treatment of HIV‑1 infection in treatment‑naïve patients 12 years of age and older with a viral load ≤100,000 HIV ‑1 RNA copies/ml AWMSG Oct 16

Rilpivirine hydrochloride EGFRvIII-positive glioblastoma multiforme – first-line SMC Aug 16

Rindopepimut Pulmonary arterial hypertension in adults NHSRIC Feb 15

Riociguat Pulmonary arterial hypertension in adults AWMSG Oct 15

Riociguat Chronic thromboembolic pulmonary hypertension in adults SMC Jul 15

Riociguat Chronic thromboembolic pulmonary hypertension in adults AWMSG Oct 15

Riociguat Non-Hodgkin's lymphoma SMC Dec 14

Rituximab (Mabthera subcutaneous) Non-Hodgkin's lymphoma AWMSG Jan 15

Rituximab (Mabthera subcutaneous) Non-Hodgkin's lymphoma NICE-ES Sep 14

Rituximab (Mabthera subcutaneous) Cutaneous scleroderma SMC Jul 14

Rituximab Minimal change disease and focal segmental glomerulosclerosis in adults NICE-ES due Mar 17 (In production)

Rituximab Autoimmune haemolytic anaemia NICE-ES Nov 16

Rituximab Idiopathic thrombocytopenic purpura NICE-ES Feb 15

Rituximab Idiopathic thrombocytopenic purpura NTAG Apr 15 Appraisal report

Rituximab Idiopathic thrombocytopenic purpura NTAG Apr 15 Recommendation

Rituximab Anti-neutrophil cytoplasmic antibody-associated vasculitis NICE-ES Oct 14

Rituximab Prevention of atherothrombotic events after acute coronary syndromes NICE Mar 14

Ribvaroxaban Prevention of atherothrombotic events after acute coronary syndromes NICE Mar 15

Ribvaroxaban Prevention of atherothrombotic events after acute coronary syndromes RDTC Oct 14 (Update)

Ribvaroxaban Prevention of atherothrombotic events after acute coronary syndromes NTAG Jun 14 Appraisal report

Ribvaroxaban Alzheimer's disease NTAG Jun 14 Recommendation

Rivastigmine Non-small cell lung cancer, advanced or recurrent with EGFR T790M mutation NICE May 16

Rociletinib Advanced BRCA-mutated ovarian cancer NHSRIC Feb 15

Rucaparib Polycythaemia vera – second-line NHSRIC Mar 16

Ruxolitinib Polycythaemia vera – second-line SMC Jun 16

Ruxolitinib Disease-related splenomegaly or symptoms in adults with myelofibrosis NICE Sep 15

Ruxolitinib Disease-related splenomegaly or symptoms in adults with myelofibrosis NICE Mar 16

Ruxolitinib Symptomatic chronic heart failure with reduced ejection fraction in adults SMC Mar 15

Sacubitril valsartan Symptomatic chronic heart failure with reduced ejection fraction in adults MTRAC May 16

Sacubitril valsartan Symptomatic chronic heart failure with reduced ejection fraction in adults NICE Apr 16

Sacubitril valsartan Parkinson's disease SMC Mar 16

Safinamide Parkinson's disease NICE-ES due TBC (In production)

Safinamide Acute myeloid leukaemia in patients not eligible for intensive treatment – first-line MTRAC Aug 16 (Update)

Sapacitabine Non-multiple sclerosis pain NHSRIC Jul 16

Sativex (cannabis-based oromucosal spray) Non-multiple sclerosis pain NTAG Dec 14 Appraisal report

Sativex (cannabis-based oromucosal spray) Moderate-to-severe active rheumatoid arthritis NTAG Dec 14 Recommendation

Sarilumab Type 2 diabetes NHSRIC Apr 15

Saxagliptin (Onglyza) In combination with insulin in adults with type 2 diabetes mellitus MTRAC May 14

Saxagliptin (Onglyza) As monotherapy in adults with type 2 diabetes mellitus SMC Nov 14

Saxagliptin (Onglyza) Lysosomal acid lipase deficiency SMC Mar 14

Sebelipase alfa Active psoriatic arthritis in adults with inadequate response to disease-modifying anti-rheumatic drug therapy, alone or in combination with methotrexate NICE due TBC (In production)

Secukinumab Active psoriatic arthritis in adults with inadequate response to disease-modifying anti-rheumatic drug therapy, alone or in combination with methotrexate NICE due Feb 17 (In production)

Secukinumab Ankylosing spondylitis – second-line SMC Aug 16

Secukinumab Ankylosing spondylitis – second-line NICE Sep 16

Secukinumab Moderate-to-severe plaque psoriasis in adults SMC Jul 16

Secukinumab Moderate-to-severe plaque psoriasis in adults NICE Jul 15

Secukinumab Pulmonary arterial hypertension (PAH) in adult SMC Jun 15

Selexipag With radioactive iodine therapy for differentiated thyroid cancer – first-line SMC due May 17 (In production)

Selumetinib KRAS mutation-positive advanced non-small cell lung cancer – second-line NHSRIC Mar 16

Selumetinib Chronic obstructive pulmonary disease NHSRIC Oct 15

Seretide Accuhaler (salmeterol xinafoate and fluticasone
Pulmonary arterial hypertension in neonates, including weaning from nitric oxide MTRAC Jan 15
propionate)

Sildenafil Digital ulcers NICE-ES Mar 16

Sildenafil Decrease of intraocular pressure in adults with open-angle glaucoma or ocular hypertension NICE-ES Mar 15

Simbrinza (brinzolomide and brimonidine tartrate) Decrease of intraocular pressure in adults with open-angle glaucoma or ocular hypertension NICE-ES Mar 15

Simbrinza (brinzolomide and brimonidine tartrate) With sofosbuvir for chronic hepatitis C SMC Nov 14

Chronic hepatitis C in adults in combination with sofosbuvir (+/- ribavirin). Licence change to remove current restriction on use only in patients intolerant of
Simeprevir NICE due TBC (In production)
interferon and in urgent need of treatment

Simeprevir Chronic hepatitis C in adults NHSRIC Apr 15

Simeprevir Chronic hepatitis C in adults NICE Feb 15

Simeprevir Liver fibrosis in patients with non-alcoholic steatohepatitis or primary sclerosing cholangitis SMC Oct 14

Simtuzumab Secondary progressive multiple sclerosis NHSRIC Jul 16

Siponimod Prostate cancer - metastatic, hormone-relapsed NHSRIC Sep 16

Sipuleucel-T Asthma NICE Feb 15

Sirdupla (salmeterol and fluticasone) Rheumatoid arthritis MTRAC Nov 15

Sirukumab Type 2 diabetes NHSRIC Aug 15

Sitagliptin Type 2 diabetes SMC Sep 15

Sitagliptin Hyperkalaemia – first-line MTRAC May 14

Sodium zirconium cyclosilicate With simeprevir for chronic hepatitis C NHSRIC Apr 15

Sofosbuvir Chronic hepatitis C NICE due TBC (In production)

Sofosbuvir Chronic hepatitis C NICE Feb 15

Sofosbuvir Chronic hepatitis C SMC Jun 14

Sofosbuvir plus GS-5816 Chronic hepatitis C NHSRIC Feb 15

Sofosbuvir, GS-9857 and velpatasvir Mild dementia due to Alzheimer’s disease NHSRIC Mar 16

Solanezumab Locally advanced or metastatic basal cell carcinoma NHSRIC Nov 16

Sonidegib (formerly erismodegib) Hepatocellular carcinoma AWMSG Dec 15

Sorafenib Hepatocellular carcinoma NICE due Mar 17 (In production – rapid review)

Sorafenib Hepatocellular carcinoma AWMSG Apr 16

Sorafenib Progressive, locally advanced or metastatic, differentiated thyroid carcinoma, refractory to radioactive iodine SMC Jan 16 (Resubmission)

Sorafenib Chronic obstructive pulmonary disease SMC Jul 15

Spiolto Respimat (tiotropium and olodaterol) Chronic obstructive pulmonary disease NICE-ES May 16

Spiolto Respimat (tiotropium and olodaterol) Gene therapy for inherited retinal dystrophies due to mutations in the RPE65 gene SMC Nov 15

SPK-RPE65 Allergic rhinitis NHSRIC Mar 16

STG 320 Hyperphosphataemia in patients with chronic kidney disease who are on dialysis NHSRIC Oct 15

Sucroferric oxyhydroxide Hyperphosphataemia in patients with chronic kidney disease who are on dialysis AWMSG Dec 15

Sucroferric oxyhydroxide Hyperphosphataemia in patients with chronic kidney disease who are on dialysis SMC Apr 15

Sucroferric oxyhydroxide Acute moderate to severe post-operative pain in adults NICE-ES Jan 15

Sufentanil Acute moderate to severe post-operative pain in adults RDTC Mar 16

Sufentanil Renal cell carcinoma – adjuvant therapy NICE-ES Mar 16

In adolescents (ages 12 to <18 years) for the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting beta2-agonist) is
Sunitinib NHSRIC May 14
appropriate

Symbicort (budesonide and formoterol) Chronic obstructive pulmonary disease SMC due TBC (In production)

Symbicort (budesonide and formoterol) Chronic obstructive pulmonary disease SMC Oct 16

Symbicort (budesonide and formoterol) Type 2 diabetes mellitus in adults – second-line MTRAC Jan 15

Synjardy (empagliflozin and metformin) Systemic lupus erythematosus SMC Oct 15

Tabalumab Prophylaxis and treatment of kidney or liver allograft rejection in adults NHSRIC May 14

Tacrolimus Prophylaxis and treatment of kidney or liver allograft rejection in adults AWMSG Sep 15

Tacrolimus Duchenne muscular dystrophy SMC Apr 15

Tadalafil Locally advanced and/or metastatic breast cancer with germline BRCA 1/2 positive mutation NHSRIC Aug 15

Talazoparib Unresectable metastatic melanoma NHSRIC Oct 15

Talimogene laherparepvec Chronic pain NICE Sep 16

Tapentadol Open angle glaucoma or ocular hypertension in adults – second-line RDTC Jan 15

Taptiqom (timolol and tafluprost) Restless legs syndrome SMC Sep 15

Targinact (oxycodone and naloxone) Chronic pain NICE-ES Dec 15

Targinact (oxycodone and naloxone) Non-24-hour sleep-wake disorder in totally blind adults RDTC Jan 15
Tasimelteon Chemotherapy-naïve, metastatic hormone-relapsed prostate cancer AWMSG Dec 15

Tasquinimod Acute bacterial skin and skin structure infections in adults NHSRIC Dec 14

Tedizolid Acute bacterial skin and skin structure infections in adults AWMSG Dec 15

Tedizolid Short bowel syndrome in children and adolescents SMC Aug 15

Teduglutide Short bowel syndrome in adults NHSRIC Jul 16

Teduglutide Nosocomial pneumonia caused by MRSA in adults SMC Feb 16

Telavancin Nosocomial pneumonia caused by MRSA in adults SMC Nov 14

Telavancin Recurrent malignant glioma NICE-ES Jul 14

Temozolomide Lamivudine-resistant hepatitis B infection in adults NICE Mar 16

Tenofovir (245mg tablets) HIV-1 infection and chronic hepatitis B infection in patients aged 12 to <18 years AWMSG May 14

Tenofovir (245mg tablets) HIV-1 infection and chronic hepatitis B infection in patients aged 12 to <18 years AWMSG Aug 13 (HIV-1 infection)

Tenofovir (245mg tablets) HIV-1 infection in patients aged 6 to <12 years AWMSG Aug 13 (Hepatitis B infection)

Tenofovir (123mg, 163mg & 204mg tablets) HIV-1 infection in patients aged 2 to <6 years, and >6 years of age for whom a solid dosage form is not appropriate AWMSG Aug 13

Tenofovir 33mg/g granules Lamivudine-resistant hepatitis B infection in adults AWMSG Aug 13

Tenofovir 33mg/g granules Chronic hepatitis B in adults and adolescents aged 12 to <18 years, for whom a solid dosage form is not appropriate AWMSG May 14

Tenofovir 33mg/g granules Monotherapy for chronic hepatitis B AWMSG Aug 13 (adolescents only)

Tenofovir alafenamide Multiple sclerosis – relapsing remitting NHSRIC Jul 15

Teriflunomide Multiple sclerosis – relapsing remitting SMC Mar 14

Teriparatide Atypical bisphosphonate-induced fractures NTAG Jun 15 Appraisal report

Teriparatide Moderate-to-severe, inadequately controlled cancer-related pain NTAG Jun 15 Recommendation

Tetrodotoxin Cystic fibrosis with a homozygous or heterozygous F508del CFTR mutation NHSRIC Aug 16

Tezacaftor and ivacaftor Epidermolysis bullosa NHSRIC Nov 16

Thymosin beta-4 Complicated intra-abdominal, skin and soft tissue infections, excluding diabetic foot infections, in children aged over 8 years NHSRIC Aug 14

Tigecycline Prevention of atherothrombotic events after myocardial infarction SMC Sep 15

Ticagrelor Prevention of atherothrombotic events after myocardial infarction SMC due Apr 17 (In production)

Ticagrelor Peripheral arterial disease NICE Dec 16

Ticagrelor Prevention of thombotic events in patients with acute ischaemic stroke or high risk transient ischaemic attack NHSRIC Aug 16

Ticagrelor Moderate-to-severe plaque psoriasis NHSRIC Apr 15

Tildrakizumab Infantile haemangioma NHSRIC Apr 15

Timolol, topical Ocular hypertension and chronic open angle glaucoma NICE-ES Aug 15

Timolol (Tiopex) Treatment and prevention of venous thromboembolism in patients with solid tumours SMC Feb 14

Tinzaparin Treatment and prevention of venous thromboembolism in patients with solid tumours AWMSG Dec 15

Tinzaparin Asthma SMC Jul 15

Tiotropium (Spiriva Respimat) Asthma AWMSG due TBC (In production)

Tiotropium (Spiriva Respimat) Asthma SMC Aug 15

Tiotropium (Spiriva Respimat) Asthma MTRAC Mar 15

Tiotropium (Spiriva Respimat) Asthma NICE-ES Mar 15

Tiotropium (Spiriva Respimat) Unresectable hepatocellular carcinoma with high c-MET expression – second-line RDTC Feb 15

Tivantinib Juvenile idiopathic polyarthritis – second-line NHSRIC Aug 16

Tocilizumab subcutaneous Juvenile idiopathic arthritis NHSRIC Jan 16

Tocilizumab Juvenile idiopathic arthritis NICE Dec 15

Tocilizumab Juvenile idiopathic arthritis AWMSG May 14

Tocilizumab Rheumatoid arthritis NICE Jan 16 (Update)

Tocilizumab Rheumatoid arthritis LMEN Sep 14 (SC preparation)

Tocilizumab Severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate SMC Aug 14 (SC preparation)

Tocilizumab Severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate SMC Oct 16

Tocilizumab Giant cell arteritis – first- and second-line SMC Dec 14

Tocilizumab Psoriatic arthritis – second or subsequent line NHSRIC Feb 14

Tofacitinib Chronic plaque psoriasis – second-line NHSRIC Jul 15

Tofacitinib Moderate-to-severe active ulcerative colitis NHSRIC Apr 15

Tofacitinib Kidney disease, autosomal dominant polycystic NHSRIC Mar 14

Tolvaptan Kidney disease, autosomal dominant polycystic SMC Jan 16

Tolvaptan Ovarian cancer – advanced, recurrent NICE Oct 15

Topotecan Ovarian cancer – advanced, recurrent NICE Apr 16

Trabectedin BRAF V600-positive melanoma – adjuvant therapy after surgical resection in combination with dabrafenib NICE Apr 16

Trametinib Unresectable or metastatic melanoma with a BRAF V600 mutation in adults – in combination with dabrafenib NHSRIC Sep 16

Trametinib Unresectable or metastatic melanoma with a BRAF V600 mutation in adults – in combination with dabrafenib SMC Sep 16

Trametinib Advanced BRAF mutated non-small cell lung cancer, in combination with dabrafenib NICE Jun 16

Trametinib Metastatic BRAF V600E-positive non-small cell lung cancer, in combination with dabrafenib NHSRIC Apr 16

Trametinib Neurogenic bowel dysfunction, chronic constipation and chronic faecal incontinence NHSRIC Aug 15

Transanal irrigation systems Neurogenic bowel dysfunction, chronic constipation and chronic faecal incontinence NTAG Apr 16 Appraisal report

HER2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction, in combination with capecitabine or 5-fluorouracil and cisplatin –
Transanal irrigation systems NTAG Apr 16 Recommendation
first-line

Trastuzumab HER2-positive, unresectable locally advanced or metastatic breast cancer SMC Oct 15 (Resubmission)

Trastuzumab emtansine (Kadcyla) HER2-positive, unresectable locally advanced or metastatic breast cancer NICE due Mar 17 (In production – rapid review)

SMC due Apr 17 (In production –

Trastuzumab emtansine (Kadcyla) HER2-positive, unresectable locally advanced or metastatic breast cancer
resubmission)

Trastuzumab emtansine (Kadcyla) HER2-positive, unresectable locally advanced or metastatic breast cancer NICE Dec 15

Trastuzumab emtansine (Kadcyla) Breast cancer – early and metastatic SMC Oct 14

Travoprost Elevated intraocular pressure in patients aged two months to <18 years with ocular hypertension or paediatric glaucoma AWMSG Nov 15

Travoprost Acne vulgaris when comedones, papules and pustules are present in patients aged 12 years or older SMC Oct 15

Treclin (clindamycin 1% and tretinoin 0.025% gel) EGFR and ALK wild-type, advanced or metastatic non-small cell lung cancer – first-line in combination with durvalumab SMC Dec 14

Tremelimumab Recurrent or metastatic squamous cell carcinoma of the head and neck – second-line in combination with durvalumab NHSRIC Dec 16

Tremelimumab Unresectable pleural or peritoneal malignant mesothelioma – second-and third-line NHSRIC Dec 16

Tremelimumab Juvenile idiopathic arthritis NHSRIC Mar 16

Triamcinolone hexacetonide Wilson’s disease SMC Nov 15

Trientine dihydrochloride Premenopausal women with early endocrine-responsive breast cancer NICE-ES due TBC (In production)

Triptorelin (Decapeptyl SR) Prostate cancer NHSRIC Jan 16

Triumeq (abacavir, dolutegravir and lamivudine) HIV infection in adults and adolescents older than 12 years of age weighing at least 40kg AWMSG May 15

Triumeq (abacavir, dolutegravir and lamivudine) Pre-exposure prophylaxis of HIV in high-risk groups SMC Dec 14
Truvada (emtricitabine and tenofovir disoproxil) Pre-exposure prophylaxis of HIV in high-risk groups SMC due Apr 17 (In production)

Truvada (emtricitabine and tenofovir disoproxil) Post-coital contraception for patients who present between 72 and 120 hours NICE-ES Oct 16

Ulipristal Post-coital contraception for patients who present between 72 and 120 hours NTAG Sep 14 - update Appraisal report

Ulipristal Intermittent treatment of moderate-to- severe symptoms of uterine fibroids in adult women of reproductive age NTAG Sep 14 - update Recommendation

Ulipristal Intermittent treatment of moderate-to- severe symptoms of uterine fibroids in adult women of reproductive age AWMSG Apr 16

Ulipristal Pre-operative treatment of moderate-to-severe uterine fibroids SMC Feb 16

Ulipristal Chronic obstructive pulmonary disease LMEN Jan 16

Ultibro Breezhaler (glycopyrronium and indacaterol

Chronic obstructive pulmonary disease MTRAC Jan 15
bromide)
Ultibro Breezhaler (glycopyrronium and indacaterol
Chronic obstructive pulmonary disease RDTC Dec 14
bromide)
Ultibro Breezhaler (glycopyrronium and indacaterol
Chronic obstructive pulmonary disease SMC Dec 14
bromide)
Ultibro Breezhaler (glycopyrronium and indacaterol
Chronic obstructive pulmonary disease AWMSG May 14
bromide)
Ultibro Breezhaler (glycopyrronium and indacaterol
Chronic obstructive pulmonary disease LMEN Feb 14
bromide)
Ultibro Breezhaler (glycopyrronium and indacaterol
Chronic obstructive pulmonary disease NICE-ES Feb 14
bromide)

Umeclidinium Chronic obstructive pulmonary disease UKMi Sep 15

Umeclidinium Chronic obstructive pulmonary disease NICE-ES Jan 15

Umeclidinium Chronic obstructive pulmonary disease AWMSG Jan 15

Umeclidinium Treatment of hepatobiliary disorders associated with cystic fibrosis in children aged 1 month to 18 years SMC Dec 14

Ursodeoxycholic acid (Ursofalk) Crohn’s disease AWMSG May 16

Ustekinumab Active psoriatic arthritis in adults – second-line NHSRIC Oct 14

Ustekinumab Active psoriatic arthritis in adults – second-line NICE Jun 15 (Rapid review)

Ustekinumab Active psoriatic arthritis in adults – second-line NICE May 14

Ustekinumab Plaque psoriasis in adolescents SMC Mar 14

Ustekinumab Plaque psoriasis in adolescents AWMSG Apr 16

Ustekinumab Aggression, agitation and behavioural disturbances in dementia SMC Jan 16

Valproate preparations Locally advanced or metastatic differentiated thyroid cancer – second-line NICE-ES Mar 15

Vandetanib Aggressive and symptomatic medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease NHSRIC Jul 15
Vandetanib Crohn’s disease – second-line AWMSG Sep 14

Vedolizumab Crohn’s disease – second-line NICE Aug 15

Vedolizumab Moderate-to-severe active ulcerative colitis in adults – second-line SMC Jul 15

Vedolizumab Moderate-to-severe active ulcerative colitis in adults – second-line NICE Jun 15

Vedolizumab Moderate-to-severe active ulcerative colitis in adults – second-line SMC May 15

Vedolizumab Moderate-to-severe active ulcerative colitis in adults – second-line NTAG Dec 14 Appraisal report

Vedolizumab Type 1 Gaucher disease NTAG Dec 14 Recommendation

Velaglucerase alfa Secondary hyperparathyroidism – first-line AWMSG Jul 14

Velcalcetide Advanced or metastatic squamous cell non-small cell lung cancer — first-line in combination with carboplatin and paclitaxel NHSRIC Feb 14

Veliparib With carboplatin and paclitaxel for early-stage triple negative breast cancer ─ neoadjuvant therapy NHSRIC Dec 16

Veliparib Metastatic BRAF V600 mutation-positive melanoma in children and adolescents NHSRIC Mar 16

Vemurafenib With rituximab for relapsed or refractory chronic lymphocytic leukaemia – second- and subsequent-line NHSRIC Jul 15

Venetoclax Chronic lymphocytic leukaemia with 17p deletion or TP53 mutation NHSRIC Jun 16

Venetoclax Vaso-occlusive crises in sickle cell disease – first-line NHSRIC Oct 15

Vepoloxamer Chronic central serous chorioretinopathy NHSRIC Jun 16

Verteporfin Chronic central serous chorioretinopathy

Verteporfin Chronic central serous chorioretinopathy NTAG Dec 14 - update Appraisal report

Verteporfin Moderate-to-severe storage and voiding symptoms associated with benign prostatic hyperplasia NTAG Dec 14 - update Recommendation

Vesomni (solifenacin and tamsulosin) Cellulitis and venous leg ulcers SMC Mar 14

Vibro-Pulse Chronic hepatitis C in adults, in combination with dasabuvir, with or without ribavirin UKMi Mar 14

Viekirax (ombitasvir, paritaprevir and ritonavir) Chronic hepatitis C in adults, in combination with or without dasabuvir SMC Jun 15

Viekirax (ombitasvir, paritaprevir and ritonavir) Type 2 diabetes NICE Nov 15

Vildagliptin Elderly patients with newly-diagnosed CD20 positive diffuse large B-cell lymphoma in combination with chemotherapy – first-line MTRAC May 14

Vincristine liposomal (Marqibo) Relapsed or refractory acute lymphoblastic leukaemia – third-line NHSRIC Oct 15

Vincristine liposomal (Marqibo) Transitional cell carcinoma of the urothelial tract NHSRIC Oct 15

Vinflunine Type 2 diabetes SMC Jul 15

Vipdomet (alogliptin and metformin) Type 2 diabetes AWMSG Oct 14

Vipdomet (alogliptin and metformin) Type 2 diabetes mellitus SMC Oct 14

Vokanamet (metformin and canagliflozin) Familial chylomicronaemia syndrome – first-line SMC Jan 15

Volanesorsen Osteoarthritis NHSRIC Jul 16

VOLT-01 (zoledronic acid/prednisolone) Severe von Willebrand disease NHSRIC Nov 16

Vonicog alfa Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant recipients NHSRIC Mar 16

Voriconazole Major depressive disorder SMC Nov 14

Vortioxetine Major depressive disorder SMC Jul 16

Vortioxetine Major depressive disorder LMEN Feb 16

Vortioxetine Post-operative inflammation and pain following cataract surgery NICE Nov 15

XG 102 Type 2 diabetes mellitus NHSRIC Sep 16

Xigduo (dapagliflozin and metformin) Type 2 diabetes mellitus SMC Aug 14

Xultophy (insulin degludec and liraglutide) Type 2 diabetes mellitus AWMSG Nov 15

Xultophy (insulin degludec and liraglutide) Type 2 diabetes mellitus SMC Oct 15

Xultophy (insulin degludec and liraglutide) Type 2 diabetes mellitus NICE-ES Jul 15

Xultophy (insulin degludec and liraglutide) Treatment of hospitalised patients with influenza RDTC May 15

Zanamivir (intravenous formulation) Chronic hepatitis C in adults NHSRIC Dec 16

Zepatier (elbasvir and grazoprevir) Chronic hepatitis C in adults SMC Jan 17

Zepatier (elbasvir and grazoprevir) Complicated intra-abdominal infections (UTI), acute pyelonephritis and complicated urinary tract infections in adults NICE Oct 16

Zerbaxa (ceftolozane and tazobactam) Complicated intra-abdominal infections (UTI), acute pyelonephritis and complicated urinary tract infections in adults AWMSG Jul 16

Zerbaxa (ceftolozane and tazobactam) Complicated intra-abdominal infections (UTI), acute pyelonephritis and complicated urinary tract infections in adults NICE-ES Jun 16 (Acute pyelonephritis/complicated UTI)

Zerbaxa (ceftolozane and tazobactam) Complicated intra-abdominal infections (UTI), acute pyelonephritis and complicated urinary tract infections in adults NICE-ES Jun 16 (Complicated intra-abdominal infections)

Zerbaxa (ceftolozane and tazobactam) Type I complex regional pain syndrome SMC May 16

Zoledronic acid (AXS 02) Adjunctive therapy for partial seizures in adolescents, and children aged six years and above NHSRIC May 16

Zonisamide Adjunctive therapy for partial seizures in adolescents, and children aged six years and above NICE-ES Mar 14

Zonisamide Adjunctive therapy for partial seizures in adolescents, and children aged six years and above SMC Mar 14
Zoptarelin doxorubicin Locally advanced, recurrent or metastatic endometrial cancer — second-line NHSRIC Jul 16